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Abstract 
Breast cancer is a leading cause of morbidity and mortality amongst adult women in Western 
Europe and North America.  Within the last decade our understanding of this condition has 
improved.  This has led to the emergence of new treatment algorithms and prognostic 
instruments. Examples of the former include taxane-based therapy and trastuzumab; further 
examples of the latter are novel prognostic instruments such as Nottingham Prognostic Index 
(NPI) and Adjuvant! Online (AO). 
 
The aim of this thesis is to determine if the application of these is associated with improved 
cancer-specific outcomes. 
 
To this end, we conducted a retrospective population-based determination of cancer-specific 
outcomes associated with newer treatment algorithms.  In addition we determined the 
correlation between prognosis and actual outcome for NPI and AO. These were compared 
with outcomes associated with prior treatment approaches.  The thesis finishes with a 
comparison of both to determine the optimal treatment management paradigm. 
 
Adjuvant taxane therapy was not associated with improved cancer-specific outcome 
compared with non-taxane based therapy.  However, third-generation (taxane-based) therapy 
was associated improved cancer-specific outcome compared with first- and second-
generation (taxane- and non-taxane based) therapy.  Adjuvant trastuzumab treatment was 




In conclusion, these practice changes have had a mixed effect on outcomes for patients with 
early-stage breast cancer (EBC).   
Keywords 
Adjuvant therapy, chemotherapy (CT), taxane-based therapy, hormonal therapy (HT), 
biological therapy (BT), trastuzumab therapy, decision-making tools, Nottingham Prognostic 
Index (NPI), Adjuvant! Online (AO), body mass index (BMI) 
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NSAID: non-steroidal anti-inflammatory 
drug 
OCP: oral contraceptive pill 
OS: overall survival 
PAS: patient administration system 
pCR: pathological complete response 
PEM: positron-emission mammography 
PET: positron-emission tomography 
PgR: progesterone receptor 
PMRT: post-mastectomy radiotherapy 
SERM: selective oestrogen receptor 
modulator 
SLNB: sentinel lymph node biopsy 
TAP: thorax, abdomen and pelvis 
TNBC: triple-negative breast cancer 
U/S: ultrasonography 
UHL: University Hospital Limerick 
WBRT: whole breast radiotherapy 
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1. Chapter One – Background 
1.1. Context 
Approximately one million new cases of female breast cancer (FBC) are diagnosed annually. 
There is significant mortality associated with FBC as more than 500 000 women‘s deaths are 
annually attributable (Groot et al. 2006, 'WHO | Cancer'  2013). It is the most common 
malignancy seen in women worldwide. It is also the most common malignancy within the 
Republic of Ireland (excluding non-melanoma skin cancers). It accounts for approximately 
33% of all female cancers diagnosed.  Whilst the EU average age-adjusted incidence rate is 
104/100 000, the corresponding rate in Ireland is 126/100 000 (Cancer in Ireland 2011: 
Annual Report of the National Cancer Registry  2011, Breast cancer incidence, mortality, 
treatment and survival in Ireland: 1994‐2009.  2012).   
 
The global incidence of FBC has been increasing steadily. This may be due to (1) the 
implementation of breast cancer mammographic screening programs (BCMS), (2) the 
increasing ageing population, (3) exposure to exogenous hormonal agents (such as hormone 
replacement therapy (HRT) and the use of the oral contraceptive pill (OCP)) and (4) lifestyle 
factors (i.e. Western diet, obesity, alcohol consumption, smoking and physical inactivity) 
(McPherson et al. 2000, 'Life Expectancy'  2010, Aebi et al. 2011, Breast cancer incidence, 
mortality, treatment and survival in Ireland: 1994‐2009.  2012, 'Breast screening'  2013). 
 
In developed countries, the mortality rates have been declining. This is attributable to (1) a 
younger patient demographic, (2) developments in adjuvant therapies, and (3) earlier 
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detection associated with BCMS programs (Berry et al. 2005, Philippe et al. 2010, Aebi et al. 
2011). 
 
1.2. Risk factors 
For most patients with breast cancer, a potential risk factor may not be identified (Lacey et al. 
2009, 'WHO | Breast cancer: prevention and control'  2012).  Table 1 lists the risk factors 
linked to FBC incidence. 
 
Factor RR 95% CI Reference 
Age at diagnosis > 10.00  (McPherson et al. 2000) 
Geographic location 5.00  (McPherson et al. 2000) 
Reproductive life 
Age of menarche 
Age of menopause 
Age at first pregnancy 
Oral contraceptive pill use 
Greater 10y after stopping 
Current user 
1 - 5y since stopping 
5 - 9y since stopping 
Hormone replacement therapy 






















0.96 – 1.05 
1.08 – 1.23 
1.02 – 1.13 
 
 
1.01 – 1.04 









(McPherson et al. 2000) 
Family history ≥ 2.00  (McPherson et al. 2000) 
Proliferative breast disease 4 - 5  (McPherson et al. 2000) 
Radiation exposure 5.00 0.80 – 12.76 (Barcellos-Hoff 2013) 
Lifestyle factors 
Increased carbohydrates 
Significant weight gain from 
21y to present 
Large body build at menarche 
















1.63 – 3.04 
0.32 – 0.83 
 
0.49 – 0.96 
0.74 – 0.98 
 
 
1.01 – 1.10 
1.06 – 1.44 
(Bluming and Tavris 
2012) 
Contralateral breast cancer > 4.00  (Lizarraga et al. 2013) 
Previous history of cancer (HL) 8.23 5.43 – 12.47 (Ibrahim et al. 2012) 
Table 1: Risk factors reported to be associated with development of breast cancer.   
Abbreviations: BMI: body mass index; CI: confidence interval; HL: Hodgkins lymphoma; RR: 





Breast cancer is very rarely seen in women less than 25 years of age. Exceptions occur in 
cases of BRCA1 and BRCA2 mutations (Balmaña et al. 2011).  In Western Europe, women 
aged less than 35 years of age account for less than 5% of all cases of FBC (Gatta et al. 2013).  
After 35 years, the incidence rises steadily until menopause, where the rate of increase 
declines (McPherson et al. 2000, Philippe et al. 2010, Cancer in Ireland 2011: Annual 
Report of the National Cancer Registry  2011).  The incidence is highest between the years of 
50 and 64, which may relate to the availability of BCMS programs (McPherson et al. 2000).  
 
1.2.2. Geographic influences 
There is significant geographic variability in age-adjusted incidence and mortality associated 
with FBC.  Both parameters vary by fivefold between developed and developing countries 
(McPherson et al. 2000, 'WHO | Breast cancer: prevention and control'  2012).  The specific 
mechanism behind this remains unclear. Contributing factors are thought to include, (1) local 
dietary factors, (2) delayed age for first pregnancy, (3) lower parity, (4) shorter breast-feeding 
practices,  (5) access to health care, and (6) lifestyles observed in developed countries (Peto 
2001, Groot et al. 2006, Markossian et al. 2013, 'WHO | Social Determinants of Health'  
2013). 
 
1.2.3. Reproductive life duration 
Prolonged exposure to endogenous oestrogens can increase the risk of developing FBC. This 
may be due to (1) an early onset of menarche, (2) late onset of menopause, (3) nulliparity, 
and (4) late age of first birth (Lacey et al. 2009).  Exposure to exogenous oestrogens, 
including the oral contraceptive pill (OCP) and hormone replacement therapy (HRT), has 
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been implicated in the development of breast cancer ('WHO | Breast cancer: prevention and 
control'  2012).   
 
1.2.4. Family history 
Family history is associated with the development of breast cancer. It accounts for 10 – 25% 
of cases in developed countries (McPherson et al. 2000, Balmaña et al. 2011).  Germ-line 
mutations that can contribute to inherited breast cancer include (1) BRCA1, (2) BRCA2, (3) 
TP53, (4) PTEN, (5) ATM and, (6) STK11 (Walsh et al. 2006, Fackenthal and Olopade 
2007).  These genes exert their oncogenic effect through multiple mechanisms which include 
altering tumour suppressor protein expression or deoxyribonucleic acid (DNA) repair 
(Turnbull and Rahman 2008).   
 
1.2.5. Proliferative breast disease 
Benign breast disease and high breast density are associated with an increased risk (see Table 
1) of developing breast cancer (McPherson et al. 2000, Tice et al. 2013).  The underlying 
mechanism is not known.   
 
1.2.6. Radiation exposure 
Exposure to radiation can increase risk of FBC development.  Evidence demonstrates that 
doses exceeding 10 cGy increase the risk of breast cancer (Barcellos-Hoff 2013). Sources of 
radiation that may exceed this threshold include (1) therapeutic thoracic radiation, (2) 
survivors of atomic detonation and, (3) persons exposed in a nuclear plant accident.  
Conventional diagnostic radiation doses as used in plain radiography or computed 
tomography do not reach this threshold. Evidence suggests that radiation exposure during 
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puberty (when there is rapid breast development) carries a greater risk than exposure in the 
post-menopausal age group (Barcellos-Hoff 2013).   
 
1.2.7. Lifestyle factors 
Certain lifestyle factors have been identified as risk factors for development of breast cancer.  
These include (1) diet high in fat, (2) high body weight, and (3) excess alcohol intake 
(McPherson et al. 2000, Hayes et al. 2013, Kruk and Marchlewicz 2013, Izano et al. 2013).  
Possible mechanisms linking diet and weight to breast cancer include signalling alterations in, 
(1) insulin-like growth factor 1 (IGF-1)/insulin/AKt pathway, (2) leptin/JAK/STAT pathway, 
and, (3) other inflammatory cascades (McPherson et al. 2000, Hayes et al. 2013).   
 
1.2.8. Contralateral breast cancer (CBC) 
Patients with FBC have an increased risk for developing CBC (Lizarraga et al. 2013). 
Patients with BRCA germ-line mutations have the highest risk of CBC.  In the absence of 
these mutations, patients with strong family histories who are diagnosed at less than 35 years 
of age with oestrogen receptor (ER) negative tumours have a high incidence of CBC. This 
risk is reduced with use of newer adjuvant treatment modalities (Balmaña et al. 2011).   
 
1.2.9. Previous history of cancer 
Patients with previous history of cancer are at an elevated risk of developing FBC.  This risk 
is especially seen in patients treated for Hodgkin lymphoma (HL), due to the administration 
of radiation using Mantle-field techniques (Ibrahim et al. 2012).   
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1.2.10. Immunosuppression  
Patients who have undergone long-term immunosuppression are at increased risk for 
developing FBC.  Patients with a liver transplantation have a two to three fold risk of 
developing de novo malignancy (Chandok and Watt 2012).  The mechanism has been related 
to (1) on-going immunosuppression, (2) increased age, (3) history of alcoholic liver disease 
or sclerosing cholangitis, and (4) smoking. FBC can account for 7.7% of post-renal 
transplantation malignancies (Kwak et al. 2013). 
 
1.3. Breast cancer risk reduction strategies 
The following are established as means of reducing breast cancer risk (McPherson et al. 2000, 
Mahoney et al. 2008). 
 
1.3.1. Pharmacotherapy 
Several medications have been investigated and shown to reduce breast cancer risk (Aebi et 
al. 2011).  These include (1) selective oestrogen receptor modulators (SERMs), (2) aromatase 
inhibitors (AIs), (3) non-steroidal inflammatory drugs (NSAIDs), and other chemo-
preventive agents (Mahoney et al. 2008). 
 
Tamoxifen is a first generation SERM.  It reduces the risk of developing invasive FBC by 
49% (RR= 0.51; 95% CI, 0.39 to 0.66) and non-invasive FBC by 59% (RR= 0.50; 95% CI 
0.33 to 0.77) (Fisher et al. 2005).  Raloxifene is a second generation SERM, that does not 
stimulate endometrial tissue like Tamoxifen (Aebi et al. 2011).  It is equivalent in reducing 
FBC risk in postmenopausal women (RR= 1.02; 95% CI, 0.82 to 1.28) (Vogel et al. 2010). 
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AIs including anastrozole, exemestane and letrozole have proven effectiveness in 
management of postmenopausal hormone receptor positive FBC (Colleoni et al. 2011).  Their 
role in risk reduction of breast cancer has been evaluated (Mahoney et al. 2008).  Anastrozole 
use was evaluated in high-risk postmenopausal women in the IBIS-II trial (Cuzick et al. 
2014).  This double-blind randomised placebo-controlled trial showed that anastrozole was 
effectively reduced incidence of FBC in high-risk postmenopausal women (HR = 0.47; 
95%CI, 0.32 - 0.68; p < 0.0001).  Exemestane use was evaluated in postmenopausal women 
in the MAP3 trial (Goss et al. 2011).  This double blind randomised placebo-controlled trial 
showed that exemestane caused a 65% relative reduction in annual incidence of FBC (HR = 
0.35; 95%CI, 0.18 – 0.70; p = 0.002) in postmenopausal women who were at moderately 
increased risk for breast cancer.   
 
NSAIDs including aspirin have been shown in some studies to reduce breast cancer risk 
(McPherson et al. 2000).  Inconsistent findings have hampered adoption into clinical practice 
(Mahoney et al. 2008).  Several novel agents are presently under evaluation for breast cancer 
risk reduction (Aebi et al. 2011, Theriault et al. 2013).  These include, (1) tyrosine kinase 
inhibitors, (2) retinoids, (3) rexinoids, (4) vitamin D analogues, and (5) green tea derivatives 
(Mahoney et al. 2008). 
 
1.3.2. Hormonal control 
Postmenopausal HRT use is known to increase breast cancer risk (Barnett et al. 2008, 
Bluming and Tavris 2012).  Avoidance or limited short term use will not increase long-term 
breast cancer risk (Mahoney et al. 2008). 
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1.3.3. Lifestyle intervention 
Lifestyle factors are known to increase breast cancer risk (see Table 1).  Recommendation is 
to maintain a weight of no more than 10 – 20kg within ideal weight at 18 years of age. This 
can reduce breast cancer risk by half (RR= 0.43; 95% CI, 0.21 to 0.86) (Mahoney et al. 2008). 
 
1.3.4. Surgical intervention 
This option usually involves prophylactic mastectomy and bilateral salpingo-oophorectomy.  
It is normally reserved for patients at a substantially increased risk of breast cancer.  This is 
usually limited to patients with genetic mutations (such as BRCA1, BRCA2, TP53 and 
PTEN) (Mahoney et al. 2008, Balmaña et al. 2011).  Similar approaches are adopted in 
patients with a strong family history of breast and/or ovarian cancer among first- and second- 
degree relatives (Balmaña et al. 2011).  Among women at moderate and high risks, bilateral 
risk-reduction mastectomy can reduce breast cancer risk by at least 89.5% (95% CI, 41% to 
100%) (Mahoney et al. 2008). 
 
1.4. Signs and symptoms 
Due to BCMS programs in Western Europe, there has been an increase in the numbers of 
patients asymptomatic at diagnosis (Breast cancer incidence, mortality, treatment and 
survival in Ireland: 1994‐2009.  2012).  With symptomatic patients, the most common 
complaint is the presence of a new painless lump or mass in the breast or axilla.  This may be 
associated with (1) the development of mastalgia or pain in the axilla, (2) new onset of nipple 
retraction or inversion or change of position, (3) skin changes (i.e. erythema, desquamation, 
dimpling, puckering or ulceration), (4) nipple discharge other than physiologic breast milk, 
(5) abnormal bleeding from breast or axilla and, (6) skin infiltration or peau d’orange 
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appearance (these are shown in Figure 1) (Barlow et al. 2002, Elmore et al. 2005, 'Signs and 
symptoms of breast cancer'  2013).  
  
 
Figure 1: Signs and symptoms of breast cancer 
 
In women who do not have a breast lump or mass at presentation, the findings of (1) breast 
asymmetry (i.e. change in size or position of one breast relative to other), (2) mastalgia or (3) 
pain in the axilla or supraclavicular fossa can prompt review by a health care professional 
('Breast cancer symptoms'  2013). 
 
1.5. Pathology 
Establishing a pathologic diagnosis is a critical step in the management of breast cancer.  
 
1.5.1. Histologic subtypes 
The majority of breast malignancies arise from epithelial elements of tissue and are termed 
carcinomas ('Pathology of breast cancer'  2013).  Breast carcinomas comprise a diverse group 
of lesions that differ in histologic appearance and biologic behaviour ('Pathology of breast 
cancer'  2013).  Invasive breast carcinomas include, (1) infiltrating ductal (76%), (2) 
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infiltrating lobular (8%), (3) mixed carcinomas, i.e. ductal and lobular (7%), (4) mucinous or 
colloid (2.4%), (5) tubular (1.5%), (6) medullary (1.2%), and (7) papillary (1%) (Li et al. 
2005).  Other less frequently seen subtypes (i.e. metaplastic breast cancer and invasive 
micropapillary breast cancer) account for less than 5% of all breast cancers ('Pathology of 
breast cancer'  2013). 
 
1.5.2. Intrinsic subtypes 
Breast cancer is heterogeneous as reflected in gene expression profiles (Sorlie et al. 2001).  
Microarray-based analyses have permitted further subtyping by combining histologic and 
immunohistochemical approaches.  The intrinsic subtypes are broken into two groups based 
on expression of hormone-receptor-related genes (Sorlie et al. 2001).  Main subtypes include: 
oestrogen receptor (ER) negative tumours (basal-like, HER2-enriched and normal-like) and 
ER positive tumours (luminal A and luminal B).  Less common breast cancer subtypes 
include, Claudin-low and luminal C (Sorlie et al. 2001, Carey et al. 2007).  The intrinsic 


















Figure 2: Intrinsic breast cancer subtypes. 
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1.5.2.1. Luminal A 
 Accounts for 50 - 60% of all breast cancers (Sorlie et al. 2003, Fan et al. 2006, Eroles 
et al. 2012). This subtype has the best cancer-specific outcome (Sorlie et al. 2003, 
Sotiriou et al. 2003).  The recurrence rate of 27.8% is lower than in other subtypes 
(Eroles et al. 2012).  
 
1.5.2.2. Luminal B 
 Accounts for 10 - 20% of all breast cancers (Fan et al. 2006, Eroles et al. 2012).  
Luminal B tumours are associated with poorer prognosis when compared with 
luminal A. This subtype can occur in clusters with poor prognosis when either 70-
genes signature assays or Oncotype Dx Recurrence score assays (Genomic Health, 
Redwood City, USA) (Fan et al. 2006, Voduc et al. 2010, Theriault et al. 2013). 
 
1.5.2.3. HER2 enriched 
 Accounts for 15 - 20% of all breast cancers (Fan et al. 2006, Eroles et al. 2012).  This 
subtype includes approximately 50% of clinically HER2 positive breast cancer, and 
carries a poor prognosis (Voduc et al. 2010).  Improvements in cancer-specific 
outcome occurred with the introduction of HER2-directed treatments (Piccart-Gebhart 
et al. 2005). 
 
1.5.2.4. Basal-like 
 Accounts for 10 – 20% of all breast cancers (Fan et al. 2006, Eroles et al. 2012).  
Clinical assays commonly refer to these tumours as ‗triple negative‘ (Olopade and 
Grushko 2001).  80% of females with BRCA1 mutation are predominantly basal-like 
in subtype (Sorlie et al. 2003).  There is a higher prevalence of this subtype in 
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premenopausal African-American women, where it accounts for approximately 30% 
of cases (Fan et al. 2006, Millikan et al. 2008).  It has a poor prognosis and high 




 Accounts for 12 – 14% of all breast cancers (Eroles et al. 2012).  This subtype is 
found in non-basal triple negative breast cancer (TNBC).  It is characterised by (1) 
low to absent expression of epithelial cell-cell adhesion genes (Claudin 3, 4 and 7, E-
cadherin), (2) luminal cell surface markers (Ep CAM and MUC1), and (3) expression 
of epithelial-to-mesenchymal transition markers, immune response genes and cancer 
stem cell markers (CD44+/CD24-, high ALDH1A1) (Carey et al. 2007).  It has a poor 
long-term cancer-specific outcome with limited response to neoadjuvant 
chemotherapy (Eroles et al. 2012). 
 
1.5.2.6. Normal-like 
 Accounts for 5 – 10% of all breast cancers (Eroles et al. 2012).  This was the first 
subtype identified (Sorlie et al. 2001).  It has similar characteristics to adipose tissue. 
It presents with a prognosis intermediate between luminal and basal-like (Eroles et al. 
2012). 
 
1.6. Diagnostic investigations 
The diagnostic evaluation of patients with a suspicion of breast cancer requires an integrated 
assessment.  This starts with a full clinical history and examination including bimanual 
palpation of both breasts and loco-regional lymph nodes.  The findings of preliminary 
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examination will influence the sequential application of diagnostic tools including, (1) breast 
imaging, (2) tissue sampling and (3) staging (for risk stratification). 
 
1.6.1. Breast imaging 
Breast imaging is an early step in the diagnostic evaluation of patients with suspected breast 
cancer.   
 
1.6.1.1. Mammography (MMG) 
This is the gold standard for detection of breast cancer in both screen and non-screen 
populations (Berman 2007, Mainiero et al. 2013). There two types are standard film-screen 
mammography (FSM) and full-field digital mammography (FFDM). FSM is advantageous 
because (1) lower costs, (2) greater availability and, (3) high spatial resolution (Berman 
2007). Limiting features include (1) immutable images (i.e. once acquired cannot be 
modified), and (2) infrastructural requirements.  FFDM is a newer technology that is limited 
by costs (Berman 2007). It is advantageous because, (1) decoupling and optimization of the 
processes of image acquisition, display and storage, (2) processing time is reduced by at least 
80%, when compared to FSM, and (3) greater flexibility in image evaluation (Berman 2007).  
Compared with FSM, the sensitivity of FFDM is higher for (1) women aged 60 – 69 years 
(89.9% versus 83.0%, p= 0.014), (2) ER negative cancer (78.5% versus 65.8%, p= 0.016), (3) 
patients with extremely dense breast (83.6% versus 68.1%, p=0.051).  Sensitivity is 
comparable for both in (1) women aged 40 – 49 years (82.4% versus 75.6%, p = 0.071), and 
(2) women aged 50 – 59 years (80.5% versus 89.7%, p=0.097) (Kerlikowske et al. 2011).  
FFDM and FSM have high specificity except for women aged 40 – 49 years (88.0% versus 
89.7%, p< 0.001). 
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The false-negative rate for conventional MMG ranges from 10 – 30% (Berman 2007).  The 
incorporation of computer-aided detection (CAD) software in conjunction with screening 
FFDM, can improve sensitivity of breast cancer detection (Morton et al. 2006, Berman 2007, 
Yang et al. 2007, Singh et al. 2008).  It has been shown to correctly identify (1) 98% of 
micro-calcification, (2) 86 – 88% of masses, and (3) 90% of all cancers (Berman 2007). 
 
1.6.1.2. Breast ultrasonography (U/S) 
Breast U/S is a useful adjunct to MMG for evaluating breast abnormalities (Sickles 2010, 
Mainiero et al. 2013).  Its use is better for (1) determining solid or cystic nature of lesions, 
and (2) visualising the denser breast in younger female patients. 
 
1.6.1.3. Breast magnetic resonance imaging (MRI) 
Breast MRI is a useful radiological investigation. It has a high sensitivity in detecting breast 
cancer, particularly when used in conjunction with clinical breast examination, MMG and 
U/S (Nunes et al. 1997).  It has proven valuable in (1) pre-operative assessment of patients 
with breast cancer, (2) follow-up patients after breast conserving surgery, (3) patients with 
equivocal conventional breast imaging, (4) women with occult breast primaries, (5) women 
with abnormal nipple discharge, (6) patients with breast implants under investigation, (7) 
patients with lobular breast cancer under evaluation and, (8) for screening high-risk patients 
(Berman 2007, Le-Petross and Shetty 2011, Mainiero et al. 2013).  Its greatest limitation is 
its poor specificity and when used in isolation can lead to a requirement for additional 
biopsies (Nunes et al. 1997, Bleicher et al. 2009). 
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1.6.1.4. Breast positron-emission tomography (PET) or positron-emission 
mammography (PEM) 
PEM is a highly specialised technique that is available only in a few centres. PEM has a 
sensitivity of 93% for known index lesions and 85% for unsuspected lesions not previously 
identified (Kalles et al. 2013).  The specificity in detecting unsuspected lesions is higher than 
MRI (74% versus 48%) (Kalles et al. 2013). 
 
1.6.2. Tissue sampling 
1.6.2.1. Fine needle aspiration cytology (FNAC) 
FNAC has been used to determine the histopathologic features of breast masses.  This 
technique is inexpensive and permits rapid and real time interpretation (Vasudev et al. 2013). 
It is limited by a high false positive rate in inexperienced hands (Aebi et al. 2011, Georgieva 
et al. 2013, Vasudev et al. 2013).  This can result in multiple biopsies that may in turn delay 
start of definitive therapy. 
 
1.6.2.2. Core needle biopsy (CNB) 
This involves the removal a core of tissue from a breast lump or mass for histologic appraisal. 
Optimal sampling occurs in conjunction with radiological guidance (Dillon et al. 2005, 
Rouse et al. 2013).  Compared to FNAC, it has lower false negative rates and can better 
differentiate between invasive and in-situ cancer (Verkooijen 2002).  CNB can permit 
determination of histological subtype and grade.  Additionally, it can also determine (1) ER 
status, (2) PgR status, (3) HER2 status, (4) lymphovascular invasion and, (5) proliferation 
indices such as Ki67 index (Hammond et al. 2010, Guiu et al. 2012, Polley et al. 2013).   
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1.6.3. Staging and risk stratification 
Staging is a classification system that allows for prognostication and the appropriate tailoring 
of treatment paradigms (Theriault et al. 2013).  In early-stage breast cancer (EBC), staging is 
confined to locoregional assessment, as asymptomatic metastatic disease is uncommon (Aebi 
et al. 2011).  In these cases, there is no proven benefit in undertaking comprehensive 
laboratory or radiological staging (Aebi et al. 2011, Theriault et al. 2013). 
 
Radiological staging should be used when (1) neo-adjuvant therapy is being considered, (2) 
there is clinical, pathological or radiological evidence of positive axillary lymphadenopathy, 
(3) large primary tumours (e.g. ≥ 5cm) and, (4) when there are signs, symptoms or abnormal 
laboratory data that raise suspicion of systemic disease (Aebi et al. 2011).  These additional 
tests may include (1) plain chest radiograph, (2) computer assisted tomography (CAT) 
scanning of the thorax, abdomen and pelvis (TAP), (3) bone scintigraphy and, (4) whole body 
PET scanning.  
 
Further risk evaluation can be obtained by integrating clinical and pathological parameters 
into scoring systems like Nottingham Prognostic Index (NPI) and Adjuvant! Online (AO).  
These prognostic tools can estimate the probability of recurrence and death from breast 
cancer (Quintyne et al. 2010).   
 
Additional prognostic and/or predictive information to complement pathology assessment can 
be obtained through use of gene expression profiles such as MammaPrint (Agendia, 
Amsterdam, the Netherlands) or Oncotype DX Recurrence Score (Genomic Health, Redwood 
City, USA) (Cardoso et al. 2008, Dowsett et al. 2010).  The MammaPrint is based on the 
Amsterdam 70-gene breast cancer gene signature.  It assesses the risk that a breast tumour 
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will metastasize to other parts of the body.  It helps physicians determine whether or not a 
patient will benefit from chemotherapy (CT).  The Oncotype DX screens for a panel of 21 
genes within a tumour to determine a recurrence score.  It helps to quantify the likelihood of 
disease recurrence in women with EBC that is oestrogen receptor (ER) positive.  The 
accurate integration of these tools into current clinical practice and added value in decision-
making is currently being evaluated in two prospective phase III trials (MINDACT and 
TAILORx). 
 
1.7. Treatment  
Breast cancer is best managed with input from a multi-disciplinary team (MDT) (Eusoma 
2000, Del Turco et al. 2010).  The MDT includes (1) breast surgeon, (2) radiation oncologist, 
(3) medical oncologist, (4) breast radiologist and, (5) pathologist specialised in breast cancer.  
Depending on the local situation and availability, other members of the MDT may include (1) 
plastic surgeons, (2) psychologists, (3) physiotherapists, (4) geneticists, and, (5) specialised 
breast nurses.  Treatment plans usually involves strategies that focus on locoregional control 
(i.e. breast surgery and radiation) and systemic control (i.e. hormonal therapy, chemotherapy 
and biological therapy) (Eusoma 2000, Fyles et al. 2004, Schmidt and Koelbl 2012).  The 
sequencing, timing and selection of these options should be planned to suit individual 
patients.  To ensure overall and optimal disease free survival, clinical and pathologic features 
need to correlate.  This information is used in tandem with patient‘s wishes when devising 




1.7.1. Breast surgery 
Definitive oncologic clearance i.e. excisional breast surgery remains the optimal means for 
locoregional control in breast cancer (Association of Breast Surgery at BASO-2009 2009).  
Whilst radical excisional surgery was initially advocated, most patients now undergo breast 
conserving surgery (BCS) (Aebi et al. 2011).  Developments in surgical approaches have 
contributed to this change. Additionally, with smaller lesions being detected through BCMS 
programs, still more conservative options are feasible (Dewis and Gribbin 2009).  For the 
remainder of patients, mastectomy is used. 
 
1.7.1.1. Breast conserving surgery (BCS) 
In wide local excision (WLE), local control and cosmesis are simultaneously addressed 
(Association of Breast Surgery at BASO-2009 2009).  For best cancer-specific outcomes, it 
requires thorough pathological assessment of resection margins and the marking of the 
tumour bed with clips to facilitate post-operative radiation (Morrow 2009).  Data 
demonstrates that the combination of BCS and post-operative radiation have better cancer-
specific outcomes when compared to BCS alone (Theriault et al. 2013).  Local recurrence 
rates of < 1% following BCS and radiation is the current standard in quality assurance (Dewis 
and Gribbin 2009). 
 
1.7.1.2. Mastectomy 
Current guidelines recommend that patients be offered a mastectomy in the following 
scenarios, (1) large tumours (e.g. > 4cm in maximum diameter), (2) multifocal tumours, (3) 
central tumours, (4) hereditary breast cancer syndromes and, (5) prior breast or chest wall 
irradiation (Aebi et al. 2011). It is important that patients be offered the option of delayed or 
immediate reconstruction (Eusoma 2000, Ho et al. 2013). 
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1.7.2. Axillary surgery 
Axillary staging relies on the histological evaluation of regional lymph nodes (Krag et al. 
2010).  This is a strong determining factor of long-term prognosis (Association of Breast 
Surgery at BASO-2009 2009).  Sentinel lymph node biopsy (SLNB) is the preferred method 
of axillary node sampling in early-stage breast cancer (Krag et al. 2010, Giuliano et al. 2011). 
It is contraindicated when there is clear clinical, pathological or radiological evidence of 
axillary involvement (Aebi et al. 2011).  It is associated with (1) low false-negative rates, (2) 
favourable isolated axillary recurrence rates, (3) less morbidity (i.e. frozen shoulder, 
lymphoedema) and, (4) shorter post-operative hospital stay (Krag et al. 2010).  The optimal 
management of micrometastatic spread and isolated tumour cells is the subject of on-going 
research.  From published reports of the IBCSG 23-01 trial, additional axillary surgery does 
not appear to be required, when a sentinel node has micrometastases (i.e. 0.2 – 2.0mm) 
(Galimberti et al. 2013).  Axillary nodal clearance (ANC) is traditionally indicated when 
there are macroscopic deposits in SLNB samples (Aebi et al. 2011, Amersi and Giuliano 
2013).  ANC is associated with 3 – 5% risk of lymphoedema, and this rises to 40% when 
adjuvant radiation is administered (Theriault et al. 2013).  However, results from recent 
Z0011 trial for patients with clinical (c) T1-T2 cN0 breast cancer with 1 – 2 sentinel lymph 
nodes containing macrometastates, treated with BCS and tangential adjuvant radiotherapy 
reported non-inferior rates of overall survival (OS), disease-free survival (DFS) and 
locoregional recurrence-free survival (Giuliano et al. 2011).  This has influenced current 
axillary surgical practice. 
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1.7.3. Radiotherapy/radiation therapy 
Radiotherapy leads to improved cancer-specific outcome (Aebi et al. 2011, Walker et al. 
2012). When whole breast radiotherapy (WBRT) is used after BCS, it reduces local 
recurrence by 67% (Clarke et al. 2005, Aebi et al. 2011).  Post mastectomy radiotherapy 
(PMRT) is only recommended after mastectomy in cases of (1) four or more positive axillary 
lymph nodes, (2) T3 (tumours > 5 cm in greatest diameter) and T4 (tumour of any size with 
direct extension to the chest wall and/or to the skin) lesions, and (3) 1 - 3 positive axillary 
lymph nodes with high risks factors (i.e. young age, lymphovascular invasion and less than 
10 nodes removed) (Clarke et al. 2005, Association of Breast Surgery at BASO-2009 2009, 
Aebi et al. 2011). 
 
1.7.4. Endocrine/hormonal therapy (HT) 
Endocrine therapy is highly recommended for all breast cancers considered to have high or 
uncertain endocrine responsiveness (i.e. ER ≥ 1%). It improves overall and disease-free 
survival (Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005).  Agent 
selection is based on individual features including menopausal status and bone density.  
 
Premenopausal patients are offered Tamoxifen (20mg once daily orally for 5 years) (Aebi et 
al. 2011).  Ovarian suppression may be necessary in patients who have ovarian function 
while on Tamoxifen.  This may be achieved surgically (i.e. bilateral salpingo-oophorectomy) 
or pharmacologically (i.e. depot administration of gonadotropin-releasing hormone analogues 
(GnRH)) (Fyles et al. 2004, Colleoni et al. 2006).  Prolonged exposure (up to a maximum of 
10 years) to Tamoxifen may be used in patients with node-positive disease or with high-risk 
features.  This has been shown to offer a survival advantage, with locoregional and distant 
relapse reduced by 36% and 13% respectively (Petrelli et al. 2013, Jordan 2014, Smith 2014).  
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It is limited however by a risk of increased toxicity.  For patients with contraindications to the 
use of Tamoxifen, a GnRH analogue or in combination with the aromatase inhibitor (AI) 
exemestane can be used (Pagani et al. 2014).  When compared with Tamoxifen, exemestane 
demonstrated (1) better disease-free survival at 5 years (91.1% versus 87.3) (HR = 0.72; 
95%CI, 0.60 – 0.85; p < 0.001) and, (2) no difference in overall survival (OS) (HR = 1.14; 
95%CI, 0.86 – 1.51; p = 0.37). 
 
Postmenopausal patients are offered AIs, this is usually a once daily preparation given over 5 
years.  AI use is associated with modest survival benefit compared to Tamoxifen (Goss et al. 
2007, Aebi et al. 2011).  An AI may however be offered for an additional 5 years following 
completion of Tamoxifen therapy.  Postmenopausal patients with node positive disease, who 
were premenopausal when they started HT, can be offered this option. 
 
1.7.5. Chemotherapy (CT) 
Adjuvant chemotherapy (CT) is recommended for (1) patients with breast cancers with 
uncertain or absent endocrine responsiveness, (2) patients with node-positive breast cancer, 
and (3) patients with breast cancer that is HER2 positive or over-expressing (Clarke et al. 
2008).  There are several adjuvant CT regimens available.  The choice of regimen is based on 
predicted toxicity profile in combination with clinical and pathological information.  CT 
selection may be, (1) anthracycline-based for patients with HER2 positive breast cancer, (2) 
taxane-based for patients with ER negative and HER2 positive breast cancer, (3) 
anthracycline- and taxane-based (given sequentially) for node positive breast cancer and, (4) 
non-anthracycline-based for patients with a strong cardiac history (Bonadonna et al. 2005, 
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005, Francis et al. 2008).  
The optimal duration of chemotherapy is unknown.  Low intensity regimens (either 
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anthracycline-based or taxane-based) are used for 12 – 16 weeks.  High intensity regimens 
(anthracycline and taxane in combination) are completed over of 18 – 24 weeks (Citron et al. 
2003).  With the introduction of weekly and dose-dense regimens the optimal duration of 
therapy is currently under review (Sparano et al. 2008). Non-anthracycline, taxane-based 
regimens (such as four cycles of docetaxel and cyclophosphamide) may be administered in 
selected patients (i.e. those at risk of cardiac complications) as an alternative to four cycles of 
anthracycline-based chemotherapy (Jones et al. 2009). 
 
1.7.6. Biological therapy (BT) 
Adjuvant therapy with trastuzumab is recommended for tumours with an over-expression of 
the HER2-protein.  The HER2-protein (i.e. p185
HER2
) is detected by IHC, e.g. 3+ using the 
HercepTest, DAKO or by HER2-gene amplification analysis by FISH or CISH (Aebi et al. 
2011).  Trastuzumab lowers the risk of recurrence by approximately one-quarter (HR = 0.54; 
95%CI, 0.43 to 0.67) and the risk of death by about one-sixth to one-third  (HR = 0.76; 
95%CI, 0.47 to 1.23) (Piccart-Gebhart et al. 2005).  In cases of, (1) smaller tumours (< 1cm), 
and (2) node negative tumours, recommendations are that risk factors (i.e. age, 
lymphovascular invasion and proliferation markers) be used to determine suitability for BT 
(Theriault et al. 2013).  Several treatment durations have been explored, and currently 12-
months is adopted (Piccart-Gebhart et al. 2005, Pivot et al. 2013).  BT can be administered 
concurrently with taxane-based CT regimens.  Concurrent use of BT is contraindicated with 
anthracycline-based CT regimens outside the clinical trial setting, due to potential 
cardiotoxicity (Theriault et al. 2013). 
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1.7.7. Neoadjuvant systemic therapy 
With greater emphasis on BCS, patients with locally advanced breast cancer can undergo 
cyto-reduction (i.e. down-staging) with systemic therapy prior to definitive surgery (Rastogi 
et al. 2008).  Thorough pre-operative pathological assessment is mandatory.  In addition, 
appropriate radiological staging is required to exclude metastatic disease (Aebi et al. 2011).  
Systemic therapy with CT, HT or BT can be offered in sequence or in combination based on 
clinical and pathologic features.  These include (1) CT for triple negative breast cancer, (2) 
CT with BT for ER negative, PgR negative and HER2 positive breast cancer, and (3) HT for 
ER positive and HER2 negative breast cancer in frail or older patients (Smith et al. 2005, von 
Minckwitz et al. 2011).  The administration of an entire course of CT upfront (neoadjuvant) 
is associated with better cancer-specific outcome compared with CT delivered in a 
fragmented manner.   This also will increase the probability of achieving a pathological 
complete response (pCR), which is a proven indicator for good prognosis.  For this same 
reason, in HER2-positive breast cancer, trastuzumab therapy should be started in the 
neoadjuvant setting in association with the taxane part of the CT regimen, to increase the 
probability of achieving a pCR.  Additionally for HER2-positive breast cancer, promising 
findings from CHER-LOB and NeoSphere studies have demonstrated increased pCR with 
trastuzumab in combination with laptinib and pertuzumab respectively (Gianni et al. 2012, 
Guarneri et al. 2012).  Neoadjuvant CT should be followed by definitive surgery, radiation 
and any other treatment (i.e. HT or BT) (Theriault et al. 2013).   Exceptions arise in cases of, 
(1) patient not tolerating therapy, (2) clinical or radiological evidence of progression on 
treatment and, (3) patient preference. 
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1.8. Objective of this study 
Improved understanding of the molecular basis of breast cancer has led to changes in 
therapeutic paradigms through alterations in adjuvant treatment modalities and directed by 
changes in prognostication. Alterations in adjuvant treatments include, (1) the introduction of 
adjuvant taxane-based CT for node positive breast cancer, and (2) introduction of adjuvant 
trastuzumab-based BT for HER2 positive breast cancer. Alterations in prognostication have 
involved the introduction of validated instruments such as NPI and AO. The data has shown 
that these alterations have resulted in improved overall survival and disease-free survival.  
 
The overall aim of this thesis is to determine if these alterations are associated with improved 
cancer-specific outcomes in the Mid-Western region of Ireland.  This will be achieved as 
follows: 
 
1. Determine clinical, demographic, pathologic and adjuvant treatment trends over a 
decade in the Mid-Western region 
2. Determine adjuvant treatment trends as they relate to taxanes and trastuzumab-based 
therapy for EBC 
3. Determine cancer-specific outcome for patients with node positive EBC who did or 
did not receive taxane-based CT 
4. Determine cancer-specific comparative outcomes for patients with HER2 positive 
EBC who did or did not receive trastuzumab-based BT 
5. Determine actual survival with survival as predicted by the NPI and AO prognostic 
tools 
6. Determine the interactions between BMI and cancer-specific outcomes for aims 1 – 5  
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2. Chapter 2 – Trends in early-stage breast cancer (EBC) from January 2001 to 






Figure 3: Map showing the Mid-Western region of Ireland. 
 
The Mid-Western region of Ireland is made up of three counties (i.e. Clare, Limerick and 
North Tipperary) (see Figure 3).  Health service delivery is administered in the region by the 
Mid-Western group of hospitals. These include, (1) University Hospital Limerick (UHL), (2) 
University Maternity Hospital, (3) Ennis Hospital, (4) Nenagh Hospital, (5) Croom Hospital 
and, (6) St. John‘s Hospital ('UL Hospitals "A single hospital system"'  2013).  The estimated 
population in the region is approximately 400 000, (i.e. 117 196 from Clare, 191 809 from 
Limerick and, 70 322 from North Tipperary) ('Population of each Province, County and City, 




Demographics and adjuvant treatment trends in EBC are similar in the Mid-Western region 
when compared with national and international trends. 
 
2.3. Aims 
The aims of this analysis were to characterize the demographics of patients with EBC in Mid-
Western Ireland.  A secondary aim was to determine trends in adjuvant therapy in EBC. 
 
2.4. Methods and Materials 
2.4.1. Generation of the Breast Cancer Database (BCD) 
A retrospective cohort-based study was designed.  The interval examined was from 1
st
 
January 2001 to 31
st
 December 2010.  Patients included were those diagnosed with early 
stage breast (EBC) cancer and referred to the Department of Medical Oncology, Mid-
Western Cancer Centre (MWCC), UHL, Limerick, Ireland.  As the histopathologic 
processing and appraisal of specimens were conducted centrally, this permitted the capture of 
all patients diagnosed with EBC. All reported cases were reviewed in breast multidisciplinary 
team (MDT) meetings.  This provided most of the cohort. This cohort was supplemented with 
patients diagnosed outside the Mid-Western region and then referred to the MWCC, UHL.  
The National Cancer Registry (NCRI) and National Cancer Control Program (NCCP) capture 
similar data nationally on a regional basis.  The data collected by these was cross-referenced 
with cohort number generated to verify it was adequately representative. 
  
A specific pro forma was designed (see Figures 5 and 6) for each patient. The parameters 
included in the pro forma ensured a comprehensive capture of the required data.  Select data 
repositories were utilised and included:  
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 UHL weekly breast MDT lists  
 Referral to the Department of Medical Oncology, UHL 
 MWCC correspondence archive  
 UHL electronic and paper records 
 UHL and St John‘s Hospital pathology and radiology records 
 UHL patient administration system (PAS) 
 UHL chemotherapy records 
 
The MWCC correspondence archive contains all correspondence originating from MWCC on 
each patient.  The first correspondence includes a comprehensive record of, (1) patient‘s 
medical history, (2) referral pathway, (3) pathologic information and, (4) adjuvant treatment 





Figure 4: Pro forma used in data collection (page 1). 
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   A4A                                                     
Version 10 – 19th June 2012 – Dr Keith Ian Quintyne MBBS MRCPI    
 
Primary Treatment: Mastectomy/Breast Conservation   
Further surgical intervention: Yes/No/NA 
· If yes, why: Cosmetic effect/Positive surgical margins/NA 
Final Treatment: Mastectomy/Breast Conservation  Date:   / /20  
If Bilateral – other side - specify:  
Primary Treatment: Mastectomy/Breast Conservation 
Further surgical intervention: Yes/No/NA 
· If yes, why: Cosmetic effect/Positive surgical margins/NA 
Final Treatment: Mastectomy/Breast Conservation  Date:   / /20  
Surgical Intervention - Lymph Nodes 
Primary Treatment: Sentinel lymph node biopsy (SLNB)/Axillary node sampling (ANS) (less than 4 
nodes)/Axillary node clearance (ANC) (level III clearance) 
Further surgical intervention: Yes/No/NA 
Final Treatment: SLNB/ANS/ANC 
If Bilateral – other side - specify: 
Primary Treatment: Sentinel lymph node biopsy (SLNB)/Axillary node sampling (ANS) (less than 4 
nodes)/Axillary node clearance (ANC) (level III clearance) 
Further surgical intervention: Yes/No/NA 
Final Treatment: SLNB/ANS/ANC 
 
Adjuvant Therapy 
Chemotherapy  Offered (Yes/No)  Date started:  / /20  







 generation  Regimen:     
Treatment completed: Yes/No/NA    
· If No, why: Not tolerated/Progressive disease/NA  
If Neo-adjuvant therapy (Clinical Stage) 
Tumour Size:   mm   Multifocal: Yes/No/NA 
T-stage:      N-stage: 
Hormonal Therapy Offered (Yes/No) 
Type offered: Tamoxifen/Anastrazole /Tam + Zoladex/Other T’ment undertaken: Yes/No/NA 
T’ment completed: Yes/No/NA 
· If No, why: Not tolerated/Progressive disease/NA/T’ment not completed 
Biological Therapy 
Herceptin offered: Yes/No/NA       T’ment undertaken: Yes/No/NA  
T’ment completed: Yes/No/NA 
· If No, why: Not tolerated/Progressive disease/NA/T’ment not completed 
Radiotherapy      Date started:  / /20  
T’ment offered: Yes/No/NA    T’ment undertaken: Yes/No/NA 
T’ment completed: Yes/No/NA 
If No, why: Not tolerated/Progressive disease/NA 
Adjuvant! Online Data 
Survival with NAT:     Survival with Chx: 
Survival with HT:     Survival with Chx + HT: 
Oncotype Dx Assay Data (Node Negatives Only) 
Test performed: Yes/No     Score: 
MD Anderson Breast Cancer Tool (Neo-adjuvant Therapy Only) 
5 year predicted survival:    10 year predicted survival: 
Survival Data 
Last Follow-up date:     First Progression date: 
Site of progression: Local/Distant/Both  If Distant, where: Bone /Brain /Lung /Liver /Other 
Status at last follow-up: Alive/Dead/Presumed Dead/Lost to Follow-up 
Miscellaneous Comments:     Ethnicity: Caucasian/Non-Caucasian/NA 
       If CT, Taxane therapy: Yes/No/NA 
 
 
Figure 5: Pro forma used in data collection (page 2). 
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2.4.2. Data validation 
The above strategy was utilized (i.e. select data repositories), as an exhaustive trawl of full 
records for every patient was not feasible.  It was necessary to determine if the data obtained 
was representative of the patients‘ full records.  To determine this, at least 10% of patients in 
each year of the study were randomly selected for direct comparison between full records and 
data in the BCD.  Due to storage of records offsite, it was not always feasible to review 
records pre-2007, but where possible this quota was met and exceeded. Each patient was 
assigned an individual number.  Numbers were selected using simple randomisation from a 
computer program ((IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp, Armonk, 
NY)). For patients selected, their full records were obtained and examined in detail.  Table 2 
demonstrates the percentage concordance and discordance between the full records and the 
BCD. In instances of discordance, data in the BCD was changed to reflect the full record. 
This process was conducted exhaustively on every parameter in the BCD.  
 














2001 81 Yes 10% 100% 89% 
2002 90 Yes 12% 100% 73% 
2003 91 Yes 13% 92% 92% 
2004 100 Yes 19% 100% 74% 
2005 93 Yes 13% 93% 100% 
2006 97 No 9% 100% 100% 
2007 109 Yes 13% 100% 50% 
2008 116 Yes 13% 100% 80% 
2009 136 Yes 22% 100% 97% 
2010 128 Yes 35% 100% 73% 
Total 1041 Yes 17%   
Table 2: Shows the records reviewed for the validation process. 
 
CT can be subdivided into three generations (i.e. first, second and third) ('Adjuvant! for 





Chemotherapy regimen Scheduled number of cycles and agents used per cycle Reference 













, given iv 3-weekly 
4 cycles of A 75mg/m
2






, given iv 3-
weekly 






, given iv 3-weekly 
 




, given iv 3-weekly 
 
 
(Fisher et al. 1990) 
(Bonadonna et al. 
1995) 
(Buzzoni et al. 
1991) 
(Lalisang et al. 
1997) 











, then 4 cycles of T 175mg/m
2
, given iv 3-weekly 




, given iv 3-weekly 






, given iv 3-weekly 






, given iv 3-weekly 
 
 
(Citron et al. 2003) 
(Jones et al. 2009) 
(Levine et al. 1998) 
(French Adjuvant 
Study Group 2001) 
 As compared to G1, G2 reduces risks of death or recurrence by an additional 15 – 20%. 
 
As compared to G1, G3 reduces risks of death or recurrence by an additional 35%. 
('Adjuvant! for 
Breast Cancer 
(Version 8.0)'  
2013) 











, then 4 cycles of T 175mg/m
2
, given iv 2-weekly 














, given iv 3-weekly 
 
 
(Citron et al. 2003) 
(Sparano et al. 
2008) 
(Martin et al. 2005) 
Abbreviations: 
A: Adriamycin; C: Cyclophosphamide; D: Docetaxel; E: Epirubicin; F: 5 Fluorouracil; M: Methotrexate; T: Paclitaxel. 
Table 3: Shows CT regimens, doses, frequency of administration and terminology used in UHL.
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2.4.3. Patient selection 
As this study was primarily focussing on adjuvant therapy, the following eligibility criteria 
were used: (1) patient age at presentation ≥ 18 years, (2) pathological data available (i.e. 
histologic sub-type, grade of differentiation, ER status, HER2 status, PgR status, tumour size, 
number of lymph nodes harvested and positive nodal count), (3) availability of completed 
records for systemic treatment (i.e. BT, CT and HT used), (4) availability of completed 
records for locoregional treatment (i.e. cytoreductive surgeries and radiation administered) 
and, (5) availability of cancer-specific outcome data.  Exclusion criterion included anyone 
with metastatic breast disease (confirmed by histopathologic or radiologic examination). 
 
2.4.4. Data analysis 
Data was entered into an Access database (Microsoft Corp, Redmond, WA).  This was 
collated and exported to Excel (Microsoft Corp, Redmond, WA), where textual errors and 
missing data were amended and inputted.  A data lock was set on 28 February 2013, to allow 
for formal evaluation.  The final data set was anonymised (i.e. all personal identifiers were 
removed) and imported to IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp, 
Armonk, NY).  The cohort was analysed by applying descriptive statistics.  Two-tailed 
significance level was p < 0.050.  Chi-square test was used for categorical data. 
 
2.4.5. Ethics Approval 
The Ethics Committee at UHL waived the requirement of approval for this study.  This was 
because (1) no potentially identifiable information would be used or released in this 
retrospective cohort-based analysis, and (2) data was already available in the NCRI and 




2.5.1. Basic demographic, clinical, pathologic and treatment results 
1041 patients with EBC were included.  The median follow-up was 5.04 years (range: 0.1 – 
12.2 years). Mean age of presentation was 55.4 years (range: 23 – 87 years; standard 
deviation (SD): 11.5 years).  The age at presentation had a normal distribution and is shown 




Figure 6: Distribution of age of presentation for patients with EBC. 
 
 56 
Figure 7 shows an age distribution in both UHL and NCRI cohorts.  The cohorts differ in age 
distribution.  In the UHL cohort, the largest group was that between 45 – 54 years at the time 
of diagnosis.  In the NCRI cohort the largest group was that greater than 64 years.  There was 
significant difference between UHL and NCRI groups (p < 0.001).  Examining the UHL 
cohort alone there was an early peak in the terms of age, whilst a step-wise increment 





















UHL 18 30 22 22
NCRI 13 25 27 34
Less than 
45 years
45 - 54 
years





Figure 7: Bar chart demonstrating distribution of patients (by age) diagnosed with early-stage 
breast cancer. 
 Two cohorts are represented (1) University of Limerick cohort (UHL) and, (2) the National Cancer 
Registry of Ireland (NCRI) cohort. 
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Table 4 is a summary of demographic data for both UHL and NCRI cohorts.  The cohorts are 
comparable in terms of (1) gender distributions and, (2) site of disease.  Statistically 
significant differences occurred in (1) mode of presentation and, (2) premorbid smoking 
status.  































































































































Table 4: Summary of demographic data from the UHL and NCRI.  
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Table 5 is a summary of clinical data for the UHL cohort.  It shows that, (1) the majority had 
a palpable mass as only symptom and, (2) the majority did not have a personal or family 
history of predisposing risk factors (i.e. DCIS, breast and/or ovarian cancer). 
 
 Variable Number Percentage (%) 
UHL 




































































































Table 5: Summary of clinical data for UHL cohort. 
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Table 6 is a summary of pathologic data for both UHL and NCRI cohorts.  The cohorts are 
comparable in terms of histologic morphology.  Significant differences occurred in (1) grade, 
(2) ER status and, (3) pathologic stage.  Matched data was not available for remaining 
parameters: (1) PgR status, (2) HER2 status, (3) multifocal disease and, (4) lymph node 
involvement.  






































































































Lymph node status 
Positive 





























Table 6: Summary of pathologic data for UHL and NCRI cohorts.  
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Table 7 is a summary of adjuvant treatment data for both the UHL and NCRI.  The cohorts 
were comparable in terms of breast surgery type.  Significant differences occurred in (1) CT, 
(2) HT and, (3) radiation administered.   Matched data was not available for remaining 
parameter: i.e. (1) axillary surgery and, (2) biological therapy. Many patients undergo BCS 
followed by further surgery predicated by margin status.   ―Definitive breast surgery type‖ 
refers the final technique of locoregional clearance was obtained.  
 
Variable Number Percentage (%) p value 
UHL NCRI 
Definitive breast surgery type 
Mastectomy 
Breast conserving surgery 














Axillary node clearance 
Axillary node sampling 
Sentinel lymph node biopsy 











































































Table 7: Summary of adjuvant treatment data for the UHL and NCRI cohorts. 
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The distribution of breast surgery type for the UHL cohort is shown in Figure 8.  It 
demonstrated an increasing trend towards BCS from 42.9% to 58.6% (p = 0.001). 
 
 
Figure 8: Stacked bar chart showing breast surgery type for UHL cohort. 
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The distribution of axillary surgery for the UHL cohort is shown in Figure 9. It demonstrates 
an increasing trend in rate of SLNB with a reduction in ANC rate from 100% to 50% (p < 
0.001).  
 
Figure 9: Stacked bar chart showing axillary surgery performed for UHL cohort. 
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The distribution of CT for the UHL cohort is shown in Figure 10.  It shows an increase in 
administration from 57.1% to 67.2% (p = 0.030). The use of neo-adjuvant CT also increased 
from 2004 to 2010. 
 
Figure 10: Stacked bar chart showing CT administered for UHL cohort. 
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The distribution by generation of CT administered for the UHL cohort is shown in Figure 11.  
The rate of G1 regimens decreased through the period 2001 to 2007.  The rate of G2 
regimens increased from 2002 to 2007, and then remained unchanged.  The rate of G3 
increased from 2004 to 2007 and thereafter plateaued. Overall a shift from predominantly G1 
regimens to G2 and G3 regimens (p < 0.001) was seen.  
 
 
Figure 11: Stacked bar chart showing CT administered by generation for UHL cohort. 
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The distribution of HT administered for the UHL cohort is shown is shown in Figure 12.  It 
demonstrates an increase in HT from 71.4% to 77.3% (p = 0.563). 
 
Figure 12: Stacked bar chart showing HT administered for UHL cohort. 
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The distribution of HT agents used for the UHL cohort is shown in Figure 13.  It shows a 
decrease in Tamoxifen use.  It shows an increase in use of AIs (i.e. anastrozole and letrozole) 
from 2003 to 2007, after which it levels off. Over the period evaluated there was a 
statistically significant reduction in the number of patients receiving Tamoxifen (p < 0.001).  
 
 
Figure 13: Stacked bar chart showing HT agents for UHL cohort. 
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The distribution of radiation administered to the UHL cohort is shown in Figure 14.  There 
was an increase in its use from 2000 to 2010 from 57.1% to 88.3% (p = 0.018). 
 




In this chapter demographic, clinical, pathologic and treatment-related information were 
reviewed.  The primary objective was to determine if there were any distinct patterns in the 
UHL cohort. 
 
The results have shown that the mean age at presentation for UHL cohort was 55.4 years 
(±11.5 years).  This is lower than the mean age 62 years reported by the NCRI (Breast cancer 
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incidence, mortality, treatment and survival in Ireland: 1994‐2009.  2012).  This difference 
was statistically significant and may be explained by the phased introduction of BCMS 
throughout Ireland from 2000 to 2007, with the service in the Mid-West starting in 2007 
('Breast screening'  2013).  This younger age at presentation can be explained by (1) greater 
proportion of younger symptomatic patients in UHL cohort and, (2) greater proportion of 
older asymptomatic patients in NCRI cohort detected by BCMS. The UHL mean is 
comparable with those of Europe and North America (Bowen et al. 2008, Partridge et al. 
2012, Howladen et al. 2013).  
 
The demographic data shows that the majority of cases (88%) were diagnosed in the Mid-
Western region.  Most patients (88%) presented symptomatically. In contrast 65% presented 
symptomatically in Ireland from 2004 to 2009 (Breast cancer incidence, mortality, treatment 
and survival in Ireland: 1994‐2009.  2012).  This finding was not unexpected given that 
BCMS became available in the Mid-Western region from 2007 ('Breast screening'  2013).  
Synchronous bilateral disease was seen in a minority (1%).  This is lower than 4.4% reported 
in the Western region of Ireland (Kheirelseid et al. 2011).  It is comparable to the 1% quoted 
by the NCRI (Breast cancer incidence, mortality, treatment and survival in Ireland: 1994‐
2009.  2012).   
 
Premorbid smoking history revealed that 44% had never smoked.  This was comparable with 
NCRI findings (Breast cancer incidence, mortality, treatment and survival in Ireland: 1994‐
2009.  2012). The proportion of (1) former smokers and, (2) patients with no available 
information was different.  The proportion of UHL ‗never smokers‘ was 44% and was lower 
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than 52.9% reported in North American studies (Braithwaite et al. 2012). The majority of 
patients were Caucasian (86%). 
 
The clinical data showed a minority (1%) had premorbid history of DCIS.  This is 
comparable to 1% in published reports (Virnig et al. 2009).  22% had a family history (not 
limited to first-degree relatives) of breast/ovarian cancer, which was comparable to quoted 
reports of less than 25% (Balmaña et al. 2011).  The majority (83%) had a palpable mass at 
presentation, which is expected as most patients were referred to the symptomatic breast 
service.  
 
The pathological data showed most breast cancers had ductal morphology (82%).  This was 
slightly higher than 75% reported by NCRI (p  = 0.516) (Breast cancer incidence, mortality, 
treatment and survival in Ireland: 1994‐2009.  2012).  The remainder of the morphological 
patterns were similar to published work nationally and internationally (Ugnat et al. 2004, 
'Pathology of breast cancer'  2013).  The majority of cases (70%) were Grade II (i.e. 
moderately differentiated) breast cancers.  This was in keeping with international data (Ugnat 
et al. 2004).  However, it was higher than 47% reported by NCRI (Breast cancer incidence, 
mortality, treatment and survival in Ireland: 1994‐2009.  2012). 75% of cases had ER 
positive breast cancer.  This was higher than national and international figures (i.e. 50% and 
67% respectively) (Campbell et al. 2010, Breast cancer incidence, mortality, treatment and 
survival in Ireland: 1994‐2009.  2012). Most cases had lymph node involvement (53%).  
This was also higher than 35% quoted in the general literature (Olivotto et al. 2005, 
'Pathology of breast cancer'  2013).  As BCMS can identify FBC at earlier stages, it may 
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account for differences in lymph node involvement (Kini et al. 1999, 'WHO | Breast cancer: 
prevention and control'  2012).  Some of the pathological data points (i.e. lymphovascular 
invasion and extranodal extension) on the pro forma were not evaluated, as these were not 
consistently reported for the majority of the UHL cohort. 
 
Adjuvant treatment data revealed that most patients (58%) had undergone mastectomy.  This 
is higher than 39% reported by NCRI for similar period (Breast cancer incidence, mortality, 
treatment and survival in Ireland: 1994‐2009.  2012).  Over the decade examined, the rate of 
BCS increased.  In 2010 the rate was 58.6%, which is below the European recommendation 
of 60% to 70% (Association of Breast Surgery at BASO-2009 2009, Aebi et al. 2011). The 
change in practice could be related to (1) expansion of breast cancer services in the Mid-
Western region, (2) implementation of BCMS in 2007 and, (3) patient preference.  The 
majority of cases (85%) underwent ANC.  This is higher than expected, given that 53% of 
cases had lymphatic metastases. Over the decade, there was a change to performing more 
SLNB, with a corresponding reduction in ANC to 50% in 2010.  This could be related to (1) 
development of breast cancer surgical services and, (2) introduction of BCMS in the Mid-
Western region.   
 
61% of the UHL group underwent CT administration.  This is greater than the 46% reported 
by NCRI (Breast cancer incidence, mortality, treatment and survival in Ireland: 1994‐2009.  
2012), which may be due to the younger demographic of the UHL group,  who would 
warrant more aggressive systemic intervention (i.e. in whom CT is often used) (Joerger and 
Thürlimann 2013). The proportion of patients who received CT during the interval examined 
increased up to 67.2% in 2010.  A change in the types of CT regimens administered (i.e. from 
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CMF-based regimens to anthracycline- and taxane- based regimens) occurred.   This may 
have been related to greater availability of more effective regimens (Swain 2011).  74% of 
cases had HT.  This is higher than the 50% reported by NCRI (Breast cancer incidence, 
mortality, treatment and survival in Ireland: 1994‐2009.  2012).  This finding is consistent 
with the rate of ER positivity (75%) in the UHL cohort.  A change in practice occurred 
relating to the types of different HT agents used, in the latter portion of the study period. This 
may have been due to availability of newer agents (i.e. AI) for use in postmenopausal patients 
(The Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists' Group 2008, Theriault 
et al. 2013). Radiation was administered to 72%, which is higher than the 59% quoted in 
NCRI data (Breast cancer incidence, mortality, treatment and survival in Ireland: 1994‐
2009.  2012).  This difference may related to, (1) increased rate of BCS being performed and, 
(2) the higher proportion of cases with lymph node metastases in the UHL cohort.  
 
2.7. Conclusions 
The aim was to determine how the characteristics of the UHL cohort compared with the 
national and international groups over a similar period.  Differences occurred for the UHL 
cohort in the following parameters: 
 Age at presentation. 
 Rate of ER positivity. 
 Rate of grade of differentiation. 
 Rate of lymph node metastases. 
 Rate of administration of CT. 
 Rate of administration of HT. 
 Rate of administration of radiation. 
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3. Chapter 3 – Impact of adjuvant taxane-based therapy in node positive EBC 
 
3.1. Background 
Adjuvant systemic therapy (i.e. BT, CT and HT) is recommended for patients with tumours 
that: (1) have uncertain or unknown endocrine receptor status, (2) are greater than one cm, (3) 
are associated with nodal involvement and, (4) have HER2 overexpression (Maughan et al. 
2010, Aebi et al. 2011).  Systemic therapies may be administered in a combination or 
sequential manner.  The combination of (1) surgical oncologic clearance and (2) adjuvant 
systemic therapies allows for optimal cancer-specific outcome (Chu et al. 2006).  In the last 
decade, systemic options (especially CT) used in management of node positive breast cancer 
have changed.  This is primarily due to development of multi-agent CT regimens that include 
a taxane-backbone (Henderson et al. 2003, Chu et al. 2006, Clavarezza et al. 2006, Francis et 
al. 2008).  Taxanes were primarily used in the treatment of metastatic breast cancer, and were 
associated with improved cancer-specific outcomes (Martin et al. 2005, Bedard and Cardoso 
2008).  Based on this, it was hypothesised that taxanes might also have benefit in the 
adjuvant setting.  This was reliant on synergism with anthracyclines coupled with the absence 
of cross-resistance (Henderson et al. 2003, Bedard and Cardoso 2008).  The improvements in 
disease-free survival (DFS) and overall survival (OS), have led to the adoption of taxanes 




The aims of this Chapter were to, (1) conduct a review of clinical trials on adjuvant taxane 
CT use in EBC, (2) determine and compare if use of adjuvant taxane-based CT was 
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associated with improved cancer-specific outcome and, (3) determine if adjuvant taxane-
based CT stratified by generation was associated with different cancer-specific outcomes. 
 
3.3. Review of clinical trials on adjuvant taxanes use in EBC 
 
3.3.1. Publication search 
Articles published from 2001 to 2010 were identified from: (1) PubMed Central/PubMed, (2) 
Web of Science, (3) Google Scholar, (4) references from citation lists in breast cancer 
management guidelines (i.e. American Society of Clinical Oncology (ASCO), European 
Society of Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN) 
and St Gallens‘.  Key search terms were, (1) adjuvant taxane therapy, (2) adjuvant docetaxel, 
(3) adjuvant paclitaxel and, (4) early-stage breast cancer.  No limitations (i.e. geographic 
location, participant‘s age or language) were imposed on the search.  Additionally, further 
reference capture was feasible by manually reviewing bibliographies from articles reviewed. 
 
3.3.2. Paper selection and quality assessment 
Paper selection and quality assessment were undertaken systematically.  The following were 
reviewed, (1) year of publication, (2) trial design, (3) patient eligibility criteria, (4) 
demographic, clinical and, pathologic baseline features, (5) dosing regimens, and (6) primary 
end-points.  The study quality was assessed using the Jadad score (Jadad et al. 1996).  This 
involved assessment of the following criteria, (1) appropriate randomization method, (2) 
appropriate blinding method and, (3) comprehensive account of all study entrants including 




Figure 15: Flow-chart demonstrating selection strategy. 
 
Potentially relevant studies identified in Pub Med,  
Web of Science, Google Scholar, and guidelines from 
ASCO, ESMO, NCCN and St Gallens‘ 
n = 188 
 
Potentially relevant studies included,  
n = 88 
Potentially relevant studies included,  
n = 30 
Studies excluded because they were duplicates,  
n = 100 
Studies excluded after full abstract text reviewed,  
n = 58 
Relevant studies included in review for this thesis,  
n = 9 
 
Studies excluded after full article text reviewed, 
on the basis of not directly addressing question,  
n = 21 
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3.3.3. Review: adjuvant taxane therapy in EBC 





Treatment Outcomes References 
CALGB 9344 3121 100% AC (60, 75, or 
90/600) x 4 q21 
vs. AC x 4 q21, T 
(175) x 4 q21. 
DFS: 65% vs. 70% 
(p = 0.001) 
OS: 80% vs. 77% 
(p = 0.008). 
(Henderson 
et al. 2003) 
NSABP B-28 3060 100% AC (60/600) x 4 
q21 vs. AC x 4 
q21, T (225) x 4 
q21. 
DFS:72% vs. 76% 
(p > 0.006) 
OS: 85% vs. 85%. 
(Mamounas 
et al. 2005) 
GEICAM 
9906 
1246 100% FEC (600/90/600) 
x 6 q21 vs. FEC x 
3 q21, T (100) x 8 
q7. 
DFS: 72.1% vs. 
78.5% (p = 0.006) 
OS: 87.1% vs. 
89.9%   (p = 0.109) 
(Martin et 
al. 2008) 
USO 9735 1016 52% AC (60/600) x 4 
q21 vs. DC 
(75/600) x 4 q21. 
DFS: 75% vs. 81% 
(p = 0.033) 
OS: 82% vs. 87% 
(p > 0.032). 
(Jones et al. 
2009) 
CALBG 9741 2005 100% A/T/C x 4+4+4 
q21 vs. A/T/C x 
4+4+4 q14 vs. 
AC/T x 4+4 q21 
vs. AC/T x 4+4 
q14. 
4-year DFS: 75% 
vs. 82% (p = 0.010) 
4-year OS: 90% vs. 
92% (p > 0.013). 
(Citron et al. 
2003) 
ECOG 1199 4950 88% A:AC/T x 4+4 q21 
B:AC x 4 q21, T x 
12 q7 
C:AC/D x 4+4 q21 
D:AC x 4 q21, D x 
12 q7. 
DFS: A vs. B (p = 
0.006), A vs. C (p 
= 0.020) 
OS: A vs. B (p = 




PACS 01 1999 100% FEC100 x 6 q21 
vs. FEC100 x 3 → 
T(100) x 3 q21. 
DFS: 73% vs. 78% 
(p = 0.012) 
OS: 87% vs. 91% 
(p = 0.017) 
(Roché et al. 
2006) 
BCIRG 001 1491 100% FAC (600/50/500) 
x 6 q21 vs. TAC 
(75/50/500) q21 
DFS: 68% vs. 75% 
(p = 0.001) 
OS: 81% vs. 87% 
(p = 0.008) 
(Hugh et al. 
2009) 
ECOG 2197 2882 100% AC (60/600) x 4 
q21 vs. AT 
(60/60) x 4 q21 
DFS: 87% vs. 85% 
(p = 0.430) 
OS: 87% vs. 91% 
(p = 0.480) 
(Goldstein et 
al. 2008) 
Table 8: Summary of clinical trials on adjuvant taxane use in EBC. 
Abbreviations: A: Adriamycin; C: Cyclophosphamide; D: Docetaxel; F: 5 fluorouracil; vs.: versus; 
DFS: disease-free survival; OS: overall survival; T: Paclitaxel. 
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3.3.3.1. Cancer and Leukaemia Group B 9344 (CALGB 9344) 
CALGB 9344 was a multicentre randomised prospective trial led by Henderson et al. 
(Henderson et al. 2003).  Patients (n = 3121) were recruited to determine whether 
anthracycline dose-escalation or introduction of paclitaxel would offer improved cancer-
specific outcome (see Table 8).  At median follow-up of 69 months it was seen that, (1) dose 
escalation of adriamycin did not improve DFS or OS, but increased haematologic toxicity, (2) 
addition of paclitaxel reduced risk of recurrence and death by approximately 20% (DFS HR, 
0.83; 95%CI, 0.73 to 0.94; p = 0.0023; OS HR, 0.82; 95%CI, 0.71 to 0.95; p = 0.0064), (3) 
subset analysis showed that ER negative tumours had better DFS benefit than ER positive 
tumours (HR, 0.72 versus HR 0.91) and, (4) further subset analysis revealed that HER2 
positive tumours had reduced risk of recurrence (HR, 0.59; p = 0.010) and death (HR, 0.57; p 
= 0.010).  Limitations for this study included, (1) variation in dosing and lengths (i.e. 4 
versus 8) of CT regimens used, (2) cohort was inadequately powered for subgroup analysis 
and, (3) absence of high-risk node negative cases of EBC. 
 
3.3.3.2. National Surgical Adjuvant Breast and Bowel Project B-28 
(NSABP B-28) 
NSABP B-28 was a multicentre international randomised trial led by Mamounas et al 
(Mamounas et al. 2005).  Patients (n = 3060) were enrolled to determine if the sequential 
administration of paclitaxel could prolong DFS and OS in node positive FBC (see Table 8).  
At median follow-up of 64 months, it was seen that addition of paclitaxel, (1) improved DFS 
by 17% (HR, 0.83; 95%CI, 0.72 to 0.95; p = 0.006) and, (2) offered no OS benefit (HR, 0.93; 
95%CI, 0.78 to 1.12; p = 0.460).  Limitations seen included, (1) higher dose of paclitaxel 
used, (2) concurrent administration of Tamoxifen, and (3) variations in durations (i.e. 4 
versus 8 cycles) of CT regimens used. 
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3.3.3.3. Grupo Español Para la Investigación del Cáncer de Mama 9906 
(GEICAM 9906) 
GEICAM 9906 was a randomized prospective trial led by Martin et al. ((Martin et al. 2008).  
Patients (n = 1246) were recruited to determine if addition of paclitaxel would improve DFS 
and OS (see Table 8).  Secondary objectives included determining if hormone receptor status 
and HER2 status had prognostic or predictive value.  At median follow-up of 66 months, it 
was noted that addition of paclitaxel, (1) improved 5 year DFS (HR, 0.74; 95%CI, 0.60 – 
0.92; p = 0.006) and, (2) without significant improvement in 5 year OS and after adjusting for 
clinical and pathologic features (i.e. lymph node status, tumour size, hormone receptor status, 
age and HT) reduced risk of relapse by 23%.  Limitations observed were (1) increased 
neurotoxicity and, (2) absence of high-risk node negative cases. 
 
3.3.3.4. United States Oncology group 9735 (USO 9735) 
USO 9735 was a randomized prospective trial led by Jones et al. (Jones et al. 2009).  Patients 
(n = 1016) were recruited to determine whether taxane-based CT produced better cancer-
specific outcome than anthracycline-based CT (see Table 8).  At median follow-up of 84 
months, docetaxel use was associated with, (1) improved DFS when compared to AC (HR, 
0.74; 95%CI, 0.56 – 0.98; p = 0.033) and, (2) improved OS when compared to AC (HR, 0.69; 
95%CI, 0.50 – 0.97; p = 0.032).  Limitations of this study included, (1) CT regimens used 
were only 4 cycles in duration and, (2) high incidence of febrile neutropaenia. 
 
3.3.3.5. Cancer and Leukaemia Group B 9741 (CALGB 9741) 
CALGB 9741 was a multicentre randomized prospective trial led by Citron et al. (Citron et 
al. 2003). Patients (n = 2005) were recruited into a 2 x 2 factorial design, to explore the 
concept of dose density of administration of CT with shortened inter-treatment interval and 
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its impact of cancer-specific outcome (see Table 8).  At median follow-up of 36 months, it 
was seen that, (1) DFS was prolonged for the cohorts receiving CT in 2-weekly (i.e. dose 
dense manner) versus those receiving 3-weekly CT (RR, 0.74; 95%CI, 0.59 to 0.93; p = 
0.010). Limitations were mainly due to increased haematologic toxicity with 3-weekly 
regimens. 
 
3.3.3.6. Eastern Cooperative Oncology Group 1199 (ECOG 1199) 
ECOG 1199 was a multicentre randomised open-labelled prospective study led by Sparano et 
al. (Sparano et al. 2008).  Patients (n = 4950) were recruited to determine the optimal, (1) 
taxane agent (i.e. docetaxel or paclitaxel) and, (2) frequency of administration (i.e. weekly or 
3-weekly) (see Table 8).  At median follow-up of 64 months, it was noted that (1) 5 year 
DFS was better with use of paclitaxel (HR, 1.27; 95%CI, 1.03 to 1.57; p = 0.006), (2) 5 year 
DFS was better with use of 3-weekly docetaxel (HR, 1.23; 95%CI, 1.00 to 1.52; p = 0.020) 
when compared to 3-weekly paclitaxel, (3) no significant benefit of receiving weekly 
docetaxel over 3-weekly paclitaxel and, (4) 5 year OS was better with weekly paclitaxel (HR, 
1.32; 95%CI, 1.02 to 1.72; p = 0.010) when compared to its 3-weekly use.  Limitations found 
were related to toxicity with weekly docetaxel group, which affected the pooled survival 
analysis. 
 
3.3.3.7. Protocole Adjuvant dans le Cancer de Sein 01 (PACS 01) 
PACS 01 was a multicentre randomised prospective study led by Roché et al. (Roché et al. 
2006).  Patients (n = 1999) were enrolled to determine if sequential administration of 
docetaxel could prolong DFS and OS in node positive EBC (see Table 8).  At median follow-
up of 60 months, it was seen that (1) 5 year DFS rates were 73.2% with FEC and 78.4% with 
FEC-D (unadjusted p = 0.011; adjusted p = 0.012), (2) multivariate analysis adjusted for 
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prognostic factors showed an 18% reduction in the relative risk of relapse with FEC-D and, 
(3) 5 year OS rates were 86.7% with FEC and 90.7% with FEC-D, demonstrating a 27% 
reduction in the relative risk of death (unadjusted p = 0.014; adjusted p = 0.017).  Limitations 
were mainly due to increased episodes of febrile neutropaenia, stomatitis, oedema and, nail 
disorders with administration of docetaxel. 
 
3.3.3.8. Breast Cancer International Research Group 001 (BCIRG 001) 
BCIRG 001 was a multicentre open-labelled prospective study led by Hugh et al. (Hugh et al. 
2009). Patients (n = 1491) were recruited to investigate the prognostic and predictive 
significance of subtyping node positive EBC by immunohistochemistry in a clinical trial of a 
docetaxel-containing regimen (see Table 8).  At median follow-up of 55 months, it was noted 
that (1) estimated rates of 5 year DFS were 75% for the DAC and 68% for the FAC group 
(absolute gain, 7%; p = 0.001) and, (2) statistically significant improvement in 5 year OS in 
favour of DAC was described (87% vs. 81%; p = 0.008).  Limitations were mainly related to 
higher incidence of febrile neutropaenia with DAC (24% vs. 2%; p < 0.001). 
 
3.3.3.9. Eastern Cooperative Oncology Group 2197 (ECOG 2197) 
ECOG 2197 was a multicentre randomised open-labelled prospective study led by Goldstein 
et al. (Goldstein et al. 2008).  Patients (n = 2882) were enrolled to determine whether 
adjuvant AT improved DFS compared with AC in node positive or high-risk node negative 
EBC (see Table 8).  At median follow-up of 79.5 months, it was seen that (1) no significant 
difference in DFS (HR, 1.02; 95%CI, 0.86 to 1.22; p = 0.780) and, (2) no significant 
difference in OS (HR, 1.06; 95%CI, 0.85 to 1.31; p = 0.620).  Limitations were primarily 




Given the findings from the review, we elected to determine if there is a difference in cancer-
specific outcome for node positive EBC treated with taxane CT as compared to those who 
were treated with non-taxane CT.   Secondly, to determine if there is a difference related to 
the generation of taxane-based CT administered. 
 
3.5. Methods and materials 
A retrospective cohort-based observation study was designed.  The subgroup was obtained 
from original UHL cohort described in Chapter 2.  
 
3.5.1. Patient selection 
This subgroup under investigation involved patients diagnosed with node positive EBC.  This 
was confirmed by pathological assessment. Exclusion criteria included, patients with node 
negative EBC and metastatic disease (both confirmed by either histopathologic or radiologic 
examination).  Inclusion criteria included: (1) patient age at presentation ≥ 18 years, (2) 
pathological data available (i.e. histologic sub-type, tumour grade of differentiation, ER 
status, HER2 status, PgR status, tumour size, number of lymph nodes harvested and positive 
nodal count), (3) availability of records of adjuvant systemic therapies administered (i.e. BT, 
CT and HT used), (4) availability of records of locoregional treatment (i.e. breast and axillary 
surgeries and radiation administered) and, (5) undergoing follow-up within Mid-Western 
regional cancer network or with listed General Practitioner (in order to obtain data on 
survival and recurrence). 
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3.5.2. Data analysis 
The collected data was analysed as described in Chapter 2 (Section 2.3.2).  Overall survival 
(OS) was calculated as the time between the histologic diagnosis and date of death or date of 
last contact.  Disease-free survival (DFS) was calculated as time between histologic diagnosis 
and date of first locoregional recurrence or first distance metastasis.  Survival curves were 
demonstrated using Kaplan-Meier estimates and compared with log rank analysis.  These 
were used to evaluate comparative cancer-specific outcomes in node positive EBC, based on 
the type of CT administered.  The cohort was analysed by applying descriptive statistics.  
Two-tailed significance level was p < 0.050.  Chi-square test was used for categorical data. 
 
3.5.3. Ethics approval 
Ethics Committee approval from Ethics Committee at UHL was waived as detailed in 
Chapter 2 (Section 2.4.5). 
 
3.6. Results 
3.6.1. Descriptive statistics 
553 patients with node positive EBC were included. The median follow-up was 59.8 months. 
The distribution of rates of taxane and non-taxane based CT administered are demonstrated in 
Table 9.  A shift occurred from the use of non-taxane CT to taxane CT between the first (7%) 
and second (93%) halves of the interval examined (p < 0.001).  The majority of taxane CT 
was administered on a 21-day cycle.  The majority of the non-taxane CT was FEC-based.  
The most commonly administered CT were second-generation regimens for both CT groups. 
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Year of CT Taxane CT Cohort Non-taxane CT Cohort 
Number Percentage (%) Number Percentage (%) 
2001 – 2005 13 7.0% 167 70.8% 
2006 - 2010 174 93.0% 69 29.2% 
Total 187 100.0% 236 100.0% 



















































Table 9: Summary of distribution of chemotherapy in UHL cohort. 
 Abbreviations: G1: first-generation; G2: second-generation; G3: third-generation. 
 
 
Table 10 is a summary of the clinical and demographic data for the UHL patients with node 
positive EBC.  Data is shown for all patients with node positive EBC, then stratified based on 
type of CT received.  Comparisons were made for those who received taxane CT and those 
who received non-taxane CT.  The median age and range were comparable between groups.  
The greatest proportion of patients with node positive EBC were between 55 – 64 years. The 
greatest proportion of patients with node positive EBC who received CT were between 45 – 
54 years.  There was no difference for age groups based on the type of CT administered.  
Majority of patients in all groups were Caucasian.  Most patients with node positive EBC 
were postmenopausal.  This held for patients who received non-taxane CT, but in taxane CT 







Variable All node positive patients Taxane CT cohort Non-taxane CT cohort p value 
n (%) Median Range n (%) Median Range n (%) Median Range 
Age (years) 
 ≤ 44 years 
 45 – 54 years 
 55 – 64 years 






















































  0.107 





















  0.001 







   
54 
65 
   
53 
88 
  0.014 
Table 10: Summary of clinical and demographic data for UHL patients. 
 Abbreviations: n: number: %: percentage; NA: not available; PS: performance status; FH: family history.  Univariate analysis performed. 
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Table 11 is a summary of the pathologic data for UHL patients with node positive EBC.  
Data is shown for all patients with node positive EBC, then stratified based by type of CT 
received.  Comparisons were made for those who received taxane CT and those who received 
non-taxane CT.  The majority had ductal carcinoma across all groups.  The greatest 
proportion of patients had moderately differentiated EBC across all groups. There was a 
statistically significant difference in proportions for grade between the CT cohorts (p = 
0.048).  The majority had positive ER status across all groups.  The majority had negative 
HER2 status across all groups.  There was a statistically significant difference in proportions 
for HER status between the CT cohorts (p < 0.001).  The median tumour size for node 
positive EBC was 2.5cm. This was comparable to non-taxane CT cohort but lower for taxane 
CT cohort.  There was a statistically significant difference in proportions for tumour size 
between CT cohorts (p = 0.002).  Most patients were N1 stage across all groups. Variation in 





Variable All node positive patients Taxane CT cohort Non-taxane CT cohort p value 
n (%) Median Range n (%) Median Range n (%) Median Range 
Histology 























  0.456 
Grade 
 I – Well 
 II – Moderately 










































87  (16) 
278 (50) 
188 (34) 








  <0.001 
Tumour size (cm)
 
 ≤ 1.00 cm 
 1.01 – 2.00 cm 

















2.5 3.0 – 9.0 0.002 
LN stage 
 N1 (1 – 3LNs) 
 N2 (4 – 9 LNs) 













  0.002 
LNR 553 0.18 0.0 – 1.0 187 0.26 0.0 – 1.0 236 0.15 0.0 – 1.0  
Table 11: Summary of the pathologic data for UHL patients.     
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Table 12 is a summary of the adjuvant treatment data for UHL patients with node positive 
EBC.  Data is shown for all patients with node positive EBC, then stratified based by type of 
CT received.  Comparisons were made for those who received taxane CT and those who 
received non-taxane CT.  The majority had a mastectomy in all groups.  Most patients in all 
groups had received HT.  A minority of patients across all groups received BT. There was a 
statistically significant difference in proportions for BT administered between the CT cohorts 
(p < 0.001).  Most patients received radiation in all groups.  There was a statistically 






Variable All node positive patients Taxane CT cohort Non-taxane CT cohort p value 
Number Percentage Number Percentage Number Percentage 
Breast surgery type 
 BCS 
 Mastectomy 






















































































































































Table 12: Summary of the adjuvant treatment data for UHL patients. 
Abbreviations: BCS: breast-conserving surgery.  Univariate analysis performed. 
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3.6.2. Survival analysis 
Figures 16 and 17 show Kaplan-Meier estimates for DFS and OS stratified by type of CT 
administered.  No significant differences in outcome emerged.  
 
 
Figure 16: Shows DFS in node positive EBC by CT administered. 
 
Figure 17: Shows OS in node positive EBC by CT administered. 
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Figures 18 and 19 show Kaplan-Meier estimates for DFS and OS stratified by type of CT 
administered.  Significant differences were seen with third-generation taxane regimens (i.e. 
AC/T (14) and AC then T (12)) having better DFS (p < 0.001) and OS (p < 0.001) than non-
taxane regimens (i.e. CMF/A-CMF and FEC).  
 
Figure 18: Shows DFS in node positive EBC by CT administered. 
 
Figure 19: Shows OS in node positive EBC by CT administered. 
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Figure 20 and 21 show Kaplan-Meier estimates for DFS stratified by type of CT 
administered and was adjusted by ER status.  Significant differences were seen with the third-
generation taxane regimens having better DFS in ER negative (p < 0.001) and ER positive (p 
= 0.004) tumours than non-taxane regimens.  
 
Figure 20: Shows DFS in ER negative node positive EBC by CT administered. 
 
Figure 21: Shows DFS in ER positive node positive EBC by CT administered. 
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Figure 22 and 23 show Kaplan-Meier estimates for OS stratified by type of CT administered 
and was adjusted by ER status.  Significant differences were seen with the third-generation 
taxane regimens having better OS in ER negative (p < 0.001) and ER positive (p = 0.001) 
tumours than non-taxane regimens.  
 
Figure 22: Shows OS in ER negative node positive EBC by CT administered. 
 
Figure 23: Shows OS in ER positive node positive EBC by CT administered. 
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Figures 24 and 25 show Kaplan-Meier estimates for DFS by type of CT administered and 
was adjusted by HER2 status.  Significant differences were seen with the third-generation 
taxane regimens having better DFS in HER2 negative (p < 0.001) and HER2 positive (p = 
0.004) tumours than non-taxane regimens.  
 
Figure 24: Shows DFS in HER2 negative EBC by CT administered. 
 
Figure 25: Shows DFS in HER2 positive EBC by CT administered. 
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Figures 26 and 27 show Kaplan-Meier estimates for OS by stratified by type of CT 
administered and were adjusted by HER2 status.  Significant differences were seen with 
third-generation taxane regimens having better OS in HER2 negative (p < 0.001) and second- 
and third-generation taxane regimens in HER2 positive (p = 0.001) tumours than non-taxane 
regimens. 
 
Figure 26: Shows OS in HER2 negative node positive EBC by CT administered. 
 
Figure 27: Shows OS in HER2 positive node positive EBC by CT administered. 
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3.6.3. Correlation and multiple regression analysis 
Correlation and multiple regression analyses in step-wise fashion were conducted to examine 
the relationship between DFS and OS and various predictors.  The predictors included, (1) 
age at diagnosis, (2) ECOG performance status, (3) menopausal status, (4) tumour size 
determined on pathologic assessment, (5) number of positive lymph nodes determined on 
pathologic assessment, (6) ER status, (7) PgR status, (8) HER2 status, and (9) receipt of 











p-value Multiple regression weights 
B β p-value 
Disease-free survival (months) 33.9 20.7      
Age at diagnosis (years) 53.7 10.3 0.084 0.228  0.097 0.374 
ECOG performance status 1 0.5 -0.208 0.069  -0.179 0.098 
Tumour size (cm) 3.36 2.03 -0.240 0.015  -0.190 0.083 
Number of positive lymph nodes 9 8 -0.150 0.091  -0.170 0.115 
ER status 
Coded: 0: positive; 1: negative 
  -0.292 0.004 -12.135 -0.292 0.008 
PgR status 
Coded: 0: positive; 1: negative 
  -0.187 0.047  -0.110 0.935 
HER2 status 
Coded: 0: positive; 1: negative 
  -0.082 0.232  -0.063 0.564 
Menopausal status 
Coded: 0: pre; 1: post 
  0.140 0.107  0.143 0.184 
Administration of taxane CT 
Coded: 0: yes; 1: no 
  0.228 0.020  0.182 0.097 
Table 13: Summary of statistics, correlations and results from regression analysis on DFS for patients with node positive EBC. 
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On univariate analysis, tumour size, ER status, and PgR status were seen to negatively and 
significantly correlate with DFS. Administration of taxane CT was positively and 
significantly correlated.  The remaining predictors were not significantly correlated with DFS. 
 
The multiple regression model was performed in a step-wise fashion with 1 of 9 predictors 
produced R
2
 = 0.292, F (1, 79) = 398.167, P = 0.008.  As can be seen in Table 13, the ER 
status had a significant negative regression weight.  This indicated that patients with ER 
positive EBC were expected to have higher DFS.  The remaining variables did not contribute 











p-value Multiple regression weights 
B β p-value 
Overall survival (months) 65.2 33.0      
Age at diagnosis (years) 52.2 9.7 - 0.149 0.001 - 0.632 - 0.183 < 0.001 
ECOG performance status 1 0.4 - 0.073 0.067  - 0.030 0.492 
Tumour size (cm) 3.08 1.70 - 0.122 0.006  -0.065 0.137 
Number of positive lymph nodes 6 6.3 - 0.084 0.045  -0.005 0.906 
ER status 
Coded: 0: positive; 1: negative 
  - 0.096 0.025  -0.074 0.092 
PgR status 
Coded: 0: positive; 1: negative 
  -0.118 0.008  -0.059 0.180 
HER2 status 
Coded: 0: positive; 1: negative 
  0.094 0.027  0.058 0.187 
Menopausal status 
Coded: 0: pre; 1: post 
  -0.099 0.022  -0.024 0.720 
Administration of taxane CT 
Coded: 0: yes; 1: no 
  0.423 < 0.001 29.054 0.437 < 0.001 
Table 14: Summary of statistics, correlations and results from regression analysis on OS for patients with node positive EBC. 




On univariate analysis, HER2 status and administration of taxane CT were seen to positively 
and significantly correlate with OS.  The remaining predictors were negatively and 
significantly correlated. ECOG performance status was negatively correlated, and not 
significant. 
 
The multiple regression model was performed in a step-wise fashion with 2 of 9 predictors 
produced R
2 
= 0.212, F (2, 414) = 864.601, p < 0.001.  As can be seen in Table 14, the 
administration of taxane-based CT had significant positive regression weight.  This indicated 
that patients not having administration of taxane CT (i.e. patients on non taxane CT) were 
expected to have a higher OS, after controlling for the other variable in the model.  Age had a 
significant negative weight, indicating that lower age was linked with a higher OS, after 
controlling for other variable in the model.  The remaining variables did not contribute to the 
model. 
 
3.6.4. Outcome at last follow-up 
The outcome for this subgroup (i.e. node positive EBC) is shown in Figure 28.  It shows the 
majority of patients (70.7%) were alive.  
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Figure 28: Pie chart shows outcome for all node positive patients. 
 
The outcome for the subgroup stratified by administration of taxane-based or non-taxane 
based CT is shown in Table 15.  Chi square analysis showed no difference for (1) 5 year DFS 
(p = 0.390) and, (2) 5 year OS (p = 0.614). 
 
Chemotherapy administered 5 year DFS 5 year OS 












Table 15: Summary of outcome for node positive patients based on CT administered. 
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The outcome for the subgroup stratified by administration of CT is shown in Table 16.  Chi 
square analysis showed statistically significant differences for (1) 5 year DFS (p < 0.001) 
and, (2) 5 year OS (p < 0.001), based on the type of CT administered. 
 
Chemotherapy administered 5 year DFS 5 year OS 
Non-taxane CT Group 
CMF/ACMF (n = 81) 
AC/EC (n = 10) 










Taxane CT Group 
AC/T (21) (n = 83) 
AC/T (14) (n = 58) 
TC/TAC (n = 12) 












Table 16: Summary of outcome for node positive patients based on CT administered. 
 
3.7. Discussion 
The primary objective was to determine if taxane CT administered to patients with node 
positive EBC, would be associated with better cancer-specific outcome than non-taxane CT. 
 
Over the period of study a change in CT practice was seen, with an increased rate of 
administration of taxanes in patients with node positive EBC (7.0% to 93.0%).  For patients 
receiving taxane-based CT, the majority (50.8%) received it in 21-day cycles.  
 
The demographic data showed that the median age for patients receiving CT was 52 and 53 
years for both cohorts.  This is comparable to the 49 – 52 seen in landmark trials (Martin et al. 
2008, Jones et al. 2009).  When CT cohorts were compared, it was noted that the taxane 
cohort had a greater proportion of younger patients.  The majority of patients evaluated were 
Caucasian, and this pattern was similar to trials (Citron et al. 2003, Jones et al. 2009).  
 101 
Premorbid smoking status revealed that the majority of patients had never smoked in both CT 
cohorts.   
 
The pathologic features of both CT cohorts in the present study differed somewhat to those 
demonstrated in previous landmark trials.  In the present study the majority had tumours ≥ 
2.01 cm (71%).  In landmark trials similar sized tumours accounted for 41 - 65% (Henderson 
et al. 2003, Mamounas et al. 2005, Martin et al. 2008).  Similar to the range in landmark 
trials (46 – 70%), the majority had 1 – 3 positive lymph nodes (56%) (46 – 70%) (Henderson 
et al. 2003, Mamounas et al. 2005, Sparano et al. 2008). The majority (76%) had ER positive 
tumours, also comparable to landmark trials (59 – 76%) (Henderson et al. 2003, Martin et al. 
2008).  A minority were HER2 positive (16%), which is slightly lower that observed in other 
studies (18 – 21%) (Martin et al. 2008, Sparano et al. 2008).   
 
The taxane CT cohort differed from the non-taxane CT cohort in that there was a, (1) greater 
proportion tumours ≥ 2.01cm (79% versus 67%) (p = 0.002), (2) greater proportion of nodal 
positivity (i.e. ≥ 4 positive lymph nodes) (58% versus 41%) (p = 0.002) and, (3) higher 
proportion of HER2 positivity (23% versus 14%) (p < 0.001).  These are less favourable 
prognostic features and can be associated with poorer cancer-specific outcome (Aebi et al. 
2011).  
 
Despite the increased proportion of poor pathologic features in the taxane CT cohort, patients 
receiving third-generation taxane CT had improved cancer-specific outcome as compared to 
patients receiving non-taxane CT.  This observation is supported by findings in landmark 
trials (Citron et al. 2003, Sparano et al. 2008).  Citron et al reported improved DFS with use 
of dose-dense regimens (i.e. third-generation taxane CT, see Table 8).  Sparano et al reported 
 102 
improved DFS and OS with use of weekly taxane CT regimens (i.e. both second- and third-
generation taxane CT, see Table 8).  
 
The CT cohorts differed in terms of treatment modalities.  Differences included, (1) higher 
numbers of cases having radiation (94.7% versus 80.1%) (p = 0.001) and, (2) higher levels of 
administration of BT (21.9% versus 7.6%) (p < 0.001) administered to taxane CT cohort.  
These findings are expected given the clinico-pathologic characteristics of both cohorts.  
Surgical treatment modalities were comparable. 
 
The survival estimates for cancer-specific outcome in node positive EBC demonstrated no 
difference for administered taxane-based and non-taxane based CT.  This might be due to (1) 
heterogeneity of the CT administered within these broad groups, (2) more unfavourable 
pathologic features in the group undergoing taxane-based CT and, (3) large selection bias that 
can be attributed to non-randomized CT allocation for the cohort.  However, with further 
stratification by generation of CT regimens, the survival estimates for cancer-specific 
outcome in node positive EBC demonstrated improved DFS (p < 0.001) and OS (p < 0.001) 
with use of taxane CT.  This finding was most prominent with use of third-generation taxane 
CT regimens.  This was supported by other observations separately noted by Citron et al. and 
Sparano et al. (Citron et al. 2003, Sparano et al. 2008).  In subgroup analysis, improved 
cancer-specific outcome observed with taxane CT was independent of ER or HER2 status.  
The benefits in cancer-specific outcome were only seen with third generation taxane CT.  An 
exception occurred in the HER2 positive group in which second- and third-generation taxane 
CT was associated with improved DFS and OS.  This observation may relate to the use of 
trastuzumab in HER2 positive patients. Synergism between taxane CT and trastuzumab BT 
has been reported (Joerger and Thürlimann 2013).   
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It was noted that the use of third-generation taxane CT was associated with improved cancer-
specific outcome when compared to second-generation taxane CT.  This is as expected. Both 
second-generation taxane and non-taxane CT regimens had comparable cancer-specific 
outcomes, as expected.  DFS and OS in were better in patients receiving third-generation 
regimens compared with second-generation regimens.  In general, the DFS and OS figures 
were comparable to published results (Citron et al. 2003, Sparano et al. 2008). 
 
3.8. Conclusions 
The aim of this Chapter was to determine and compare cancer-specific outcome in taxane and 
non-taxane CT in node positive EBC. Cancer-specific outcome was improved in the cohort 
that received third-generation taxane-based CT.  This was independent of ER and HER2 
status.  Comparable outcomes were seen with taxane-based and non-taxane based second-
generation CT. 
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4. Chapter 4 – Impact of adjuvant trastuzumab therapy in HER2 positive EBC 
 
4.1. Background 
The HER group of proteins are Type I trans-membrane tyrosine kinase receptors. These 
include: (1) HER1 (EGFR), (2) HER2 (HER2-neu), (3) HER3 and, (4) HER4 (Baselga 2010).  
HER2 regulates receptors has been shown to control cellular growth, differentiation and 
death (Yarden and Sliwkowski 2001, Gschwind et al. 2004).  HER2 over-expression (i.e. 
HER2 positive breast cancer) is associated with, (1) poor prognosis, (2) increased risk of 
recurrence and, (3) more aggressive biological phenotype (Kelly et al. 2011, Soria et al. 
2011). 15 – 20% of FBC are HER2 positive (Slamon et al. 1987, Slamon et al. 1989, Brufsky 
2010). 
 
In the last decade, there has been significant progress in the understanding of the molecular 
behaviour of breast cancer. This has led to the development of new agents that can counteract 
aberrant molecular targets.  Therefore highlighting its role as a prognostic marker, but also 
shows that HER2 overexpression can be predictive for response to anti-HER2 therapy.  BT 
agents exert their effects by preventing: (1) ligand binding, (2) dimerization, (3) recruitment 
of antibody-dependent cell-mediated cytotoxicity and, (4) recruitment of downstream 
signalling proteins (Baselga 2010).  Agents currently available include (1) trastuzumab, (2) 
lapatinib, (3) pertuzumab and, (4) T-DM1.  The treatment with these agents has been shown 
to substantially improve survival in patients with HER2 positive EBC (Wolff et al. 2013).   
 
Trastuzumab (Herceptin; Roche, Basel, Switzerland), a humanised monoclonal antibody was 
initially seen to improve cancer-specific outcome in metastatic HER2 positive FBC (Piccart-
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Gebhart et al. 2005).  The oncologic effect was seen, whether administered as a single agent 
or in combination with CT (Vogel et al. 2002, Baselga et al. 2005).  It exerts its therapeutic 
effect by targeting the extracellular portion of the HER2 transmembrance receptor.  The 
toxicity profile of trastuzumab differs from that of traditional CT with fewer reports of 
alopecia, emesis or myelosupression. Cardiotoxicity and hypersensitivity reactions appear 
increased with trastuzumab usage (Bell 2002, Vogel et al. 2002). Given the above toxicity 
profile, trastuzumab was combined with traditional CT regimens.  In general this involves the 
sequential administration of BT following CT as this reduces potential cardiotoxicity 
(Piccart-Gebhart et al. 2005, Theriault et al. 2013). 
 
Concomitant with the development of anti-HER2 therapy, assays were developed to 
determine HER2 positivity and, hence potential benefit from therapy.  HER2 testing can be 
performed by measuring protein expression with IHC assays or by measuring gene 
expression with FISH assays.  Two IHC assays were recognised by US Food and Drug 
Administration (FDA) for the measurement of HER2 protein overexpression: HercepTest 
(Dako Corporation; Glostrup, Denmark) and Pathway (Ventana Medical Systems; Tucson, 
AZ) ('PATHWAY HER2/neu'  2009, 'HercepTestâ„¢ Interpretation Guides'  2015).  Initially, 
these assays defined protein positivity as a score of 2+ and 3+.  By definition, a 2+ score 
represents moderate circumferential membrane staining in > 10% of the invasive tumour cells, 
with a 3+ score representing complete circumferential membrane staining observed in > 10% 
of the invasive tumour cells.  Subsequent to the original definitions, retrospective and sub-
group analyses showed that only patients with 3+ IHC score benefited from anti-HER2 
therapy (Slamon et al. 2001, Vogel et al. 2002, Dressler et al. 2005). The 2+ protein 
expression was subsequently defined as ‗intermediate‘ and found to correlate with gene 
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amplification in only 12% - 25% of cases (Lebeau et al. 2001, Perez et al. 2002, Dybdal et al. 
2005). 
 
More recently, FISH assays, which measure HER2 gene amplification, have also become 
available for testing of HER2 status.  Three FISH assays have since gained FDA approval: 
Inform (Ventana Medical Systems; Tucson, AZ), PathVysion (Abbott Molecular; Abbott 
Park, IL) and, PharmDx (Dako Corporation; Glostrup, Denmark).  Guidelines for the use of 
these assays define HER2 amplification as a HER2 gene-to-centromere ratio of > 2.0 or an 
absolute gene copy number of > 4.  Historically, then, a 3+ score by IHC or a FISH ratio of 
2.0/absolute gene copy > 4 was considered HER2 overexpression/positive.  However, early 
analysis of HER2 testing by IHC and FISH in the large central laboratories of the prospective 
randomized adjuvant trials of trastuzumab, compared with local laboratories using both 
techniques, demonstrated variability in the ability to corroborate HER2 positivity (IHC 3+ or 
FISH +) in the range of 10% - 20% (Paik et al. 2002, Perez et al. 2006).  In response, several 
expert guidelines were generated.  The most influential of these guidelines was established as 
a collaborative effort between ASCO and the College of American Pathologists (CAP) in 
2007. 
 
In 2013, the ASCO/CAP updated its guidelines (Wolff et al. 2013).  It recommended that 
HER2 status (HER2 negative or positive) be determined in all patients with invasive (early-
stage or recurrent) breast cancer on the basis of one or more HER2 test results (negative, 
equivocal, or positive).  Testing criteria define HER positive status when (on observing 
within an area of tumour that amounts to > 10% of contiguous and homogenous tumour cells) 
there is evidence of protein overexpression (IHC) or gene amplification (HER2 copy number 
or HER2/CEP17 ratio by FISH/CISH based on counting at least 20 cells within the area).  If 
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results are equivocal (revised criteria), repeat testing should be performed using an alternative 
assay (IHC or FISH).  Repeat testing should be considered if results seem discordant with 
other histopathologic findings.  These guidelines are essential, because despite its many 
benefits, trastuzumab is not without its disadvantages. These include (1) adjuvant BT for 52 
weeks can be costly and, (2) 1% - 4% risk of serious cardiac events (including symptomatic 
heart failure) (Perez et al. 2011, Wolff et al. 2013).  
 
4.2. Aims 
The aims of this Chapter were to, (1) conduct a review of clinical trials on adjuvant 
trastuzumab use in EBC, and (2) determine and compare if use of adjuvant trastuzumab was 
associated with improved cancer-specific outcome for EBC in UHL cohort.  
 
4.3. Review of clinical trials on adjuvant trastuzumab in EBC 
4.3.1. Publication search 
Articles published from 2004 to 2014 were identified from several sources.  These included, 
(1) PubMed Central/PubMed, (2) Web of Science, (3) Google Scholar, (4) references from 
citation lists in breast cancer management guidelines (i.e. American Society of Clinical 
Oncology (ASCO), European Society of Medical Oncology (ESMO), National 
Comprehensive Cancer Network (NCCN) and St Gallens‘.  Key words used for the search 
were, (1) adjuvant trastuzumab therapy and, (2) early-stage breast cancer.  No limits were 
imposed (i.e. geographic location, participant‘s age or language) were used for this search.  
Additionally, further reference capture was feasible by manually reviewing bibliographies 
from articles collected. 
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4.3.2. Paper selection and quality assessment 
Paper selection and quality assessment were undertaken systematically.  This was done in 
comparable fashion as detailed in Chapter 3 (Section 3.3.2).  The articles reviewed are 




Figure 29: Flow-chart demonstrating selection strategy. 
Potentially relevant studies identified in Pub Med,  
Web of Science, Google Scholar, and guidelines from 
ASCO, ESMO, NCCN and St Gallens‘,  
n = 86 
 
Potentially relevant studies included,  
n = 44 
Potentially relevant studies included,  
n = 18 
Studies excluded because they were duplicates,  
n = 42 
Studies excluded after full abstract text reviewed,  
n = 26 
Relevant studies included in review for this thesis,  
n = 6 
 
Studies excluded after full article text reviewed, 
on the basis of not directly addressing the question,  
n = 12 
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4.3.3. Review: adjuvant trastuzumab therapy in EBC 
 
The six reviewed studies are summarised in Table 17. 
Trial Cohort 
size 




3351 AC x 4 q21, T x 4 q21 
or T x 12 q7 vs. AC x 4 
q21, T x 4 q21 or t x 12 
q7, H x 52 q7 vs. AC x 
4 q21, T x 12 q7, H x 
52. 
DFS: control arm, 
73.1%; H arm, 85.9%. 
HR, 0.49; p < 0.001. 
OS: control arm, 
89.4%; H arm, 92.6%. 





3401 (Neo) adjuvant CT x 4 
vs. (Neo) adjuvant CT x 
4, H x 18 q21 vs. (Neo) 
adjuvant CT x 4, H x 35 
q21. 
 
DFS: control arm, 
74.3%; H arm, 80.6%.  
HR, 0.64; p < 0.001. 
OS: control arm, 
89.7%; H arm, 92.4%.  




FinHer 1010 D/V x 3 q21, FEC x 3 
q21 vs. D/V x 3 q21, 
FEC x 3 q21, H x 52 q 
7. 
DFS: D FEC arm, 
86.8%; V FEC arm, 
81.6%.  HR, 0.66; p = 
0.010. 
H arm, 83.3%; control 
arm, 73.0%.  HR, 0.65; 
p = 0.120. 
(Joensuu et 
al. 2009) 
NOAH 334 (Neo) adjuvant CT, H x 
52 q7 vs. (Neo) 
adjuvant CT in HER2 
positive vs. Adjuvant 
CT in HER2 negative. 
DFS: H arm, 71%; 
control arm, 56%.  HR, 
0.59; p = 0.013. 
(Gianni et 
al. 2010) 
BCIRG 006 3222 AC x 4 q21, D x 4 q21 
vs. AC x 4 q21, D x 4 
q21, H x 52 q7 vs. 




DFS: control arm, 75%; 
AC→DH arm, 84%.  
HR, 0.64; p < 0.001. 
CD→H arm, 81%.  HR, 
0.75; p = 0.040. 
OS: control arm, 87%; 
AC→DH arm, 92%.  
HR, 0.63; p <0.001.  
CD→H arm, 91%.  HR, 





3384 Adjuvant CT, H x 9 q21 
vs. Adjuvant CT, H x 
18 q21. H administered: 
concurrently or 
sequentially 
DFS:  12-month arm, 
93.8%, 6-month arm, 
91.1%.  HR, 1.28; p = 
0.290. 
(Pivot et al. 
2013) 
Table 17: Summary of clinical trials on adjuvant trastuzumab use. 
 Abbreviations: DFS: disease-free survival; H: trastuzumab; Carbo: carboplatin; OS: overall survival; 
V: vinorelbine; vs.: versus. 
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4.3.3.1. National Surgical Adjuvant Breast and Bowel Project B-31 
(NSABP B-31) and North Central Cancer Treatment Group trial 
N9831 (NCCTG N9831) 
NSABP B-31 and NCCTG N9831 combined findings for this multicentre retrospective 
analysis trial that was led by Romond et al. (Romond et al. 2005).  Patients (n = 3351) were 
recruited to determine whether trastuzumab administered with adjuvant CT would offer 
improved cancer-specific outcome (see Table 17).  At median follow-up of 2.9 years, the 
following were observed: (1) 12% absolute improvement in 3 year DFS between trastuzumab 
and control groups (HR = 0.48;95%CI: 0.39 to 0.59; p < 0.0001), (2) 33% reduction in risk of 
death (HR = 0.66;95%CI: 0.47 to 0.94; p = 0.015) with trastuzumab and, (3) on subgroup (i.e. 
node negative and low grade EBC) analysis, there was no preferential benefit with use of 
trastuzumab. Limitations of this study were mainly related to the non-inclusion of node 
negative HER2 positive EBC cases. 
 
4.3.3.2. Breast International Group 01-01 (BIG 01-01): The Herceptin 
Adjuvant (HERA) trial 
HERA (n = 3401) was a multicentre international randomised open-labelled trial led by 
Piccart-Gebhart et al. (Piccart-Gebhart et al. 2005).  The end points included activity, 
efficacy and optimal duration of adjuvant trastuzumab therapy following locoregional (i.e. 
breast and axillary surgeries with or without radiation) and systemic therapies (i.e. adjuvant 
or neoadjuvant CT) (see Table 17).  At median follow-up of 23.5 months, trastuzumab was 
associated with (1) improved DFS of 8.4% (HR, 0.54; 95%CI, 0.43 to 0.67; p < 0.001) and, 
(2) similar OS to that observed with CT.  In the initial report Arm C (combined CT and BT) 
was not included in the evaluation, representing a limitation of the study.  Subsequent reports 
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from this trial have demonstrated that the benefits of trastuzumab persisted over the long term 
and that treatment for 12 months is associated with optimal cancer-specific outcome 
(Goldhirsch et al. 2013a). 
 
4.3.3.3. Finland Herceptin Trial (FinHer) 
FinHer was a multicentre randomised open-labelled trial (Joensuu et al. 2009).  Patients (n = 
1010) were enrolled to evaluate docetaxel or vinorelbine, with or without trastuzumab, as 
adjuvant treatments for EBC (see Table 17).  At median follow-up of 62 months, it was 
noted that (1) administration of docetaxel had better DFS than vinorelbine (HR = 
0.66;95%CI: 0.49 to 0.91; p = 0.010), (2) administration of trastuzumab tended to have better 
DFS than control arm (HR= 0.65;95%CI: 0.38 to 1.12; p = 0.120; with adjustment for 
presence of axillary nodal metastases, HR = 0.57; p = 0.047) and, (3) in exploratory analyses, 
docetaxel, trastuzumab and, FEC improved DFS compared to docetaxel plus FEC (HR = 
0.32; p = 0.029) and vinorelbine, trastuzumab and, FEC (HR = 0.31; p = 0.020).  Limitations 
of this study were related to non-inclusion of HER2 positive EBC less than 2.0cm. 
 
4.3.3.4. NeoAdjuvant Herceptin trial (NOAH) 
NOAH was a randomised control trial led by Gianni et al. (Gianni et al. 2010).  Patients (n = 
334) were recruited to assess event-free survival in patients with HER2 positive locally 
advanced or inflammatory breast cancer receiving neoadjuvant CT with or without 1 year of 
trastuzumab (see Table 17).  At median follow-up of 36 months, trastuzumab was associated 
with (1) significantly improved event-free survival in patients with HER2 positive EBC (3-
year event-free survival, 71%  (95%CI: 61 – 78%; n = 36 events) versus 56% (95%CI: 46 – 
54%;n = 51 events) without trastuzumab; (HR = 0.59; 95%CI: 0.38 to 0.90; p = 0.013) and, 
(2) good tolerance, despite concurrent administration with an anthracycline.  Limitations of 
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this study included, (1) small sample size and, (2) concurrent administration of trastuzumab 
with doxorubicin (which is contraindicated in clinical setting). 
 
4.3.3.5. Breast Cancer International Research Group 006 (BCIRG – 006) 
BCIRG – 006 was a multicentre international randomised open-labelled trial (Slamon et al. 
2011).  Patients (n = 3222) were recruited to evaluate the efficacy and safety of trastuzumab 
combined with anthracycline and non-anthracycline regimens (see Table 17).  This study was 
not prospectively designed or powered for any direct comparisons between AC/T and TCH 
CT regimens.  At median follow-up of 65 months it was seen that, (1) there was no 
significant difference in efficacy (i.e. DFS or OS) between groups compared that contained 
trastuzumab and, (2) rates of cardiotoxicity were higher in the group receiving an 
anthracycline/trastuzumab when compared with those with the non-
anthracycline/trastuzumab group (p<0.001).  The study was underpowered for efficacy 
(authors own admission).  Outcomes for tumours less than 1 cm were not discussed.  Taxane 
used was docetaxel and not paclitaxel (which is more frequently used in UHL).  
 
 
4.3.3.6. French National Cancer Institute (INCa): Protocol for Herceptin 
as Adjuvant Therapy with Reduced Exposure (PHARE) trial 
More recently, PHARE, was an open-labelled multicentre randomised prospective trial led by 
Pivot et al. (Pivot et al. 2013).  Patients (n = 3384) were enrolled to compare the efficacy of 
six versus twelve months of trastuzumab therapy in HER positive EBC given every 21 days  
(see Table 17).   At median follow-up of 42.5 months it was noted that, (1) 2 year DFS was 
93.8% (95%CI, 92.6 to 94.9%) for 12 months of trastuzumab and 91.1%(95%CI, 89.7 to 
92.4%) for 6 months of trastuzumab (HR, 1.28; 95%CI 1.05 to 1.56; p = 0.29) and, (2) 
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significantly more patients in the 12 month group experienced cardiotoxicity than in 6 month 
group (5.7% versus 1.9%; p < 0.0001).  Limitations seen in this study were, (1) 
inconsistencies due to diversity of adjuvant CT and surgery used and, (2) inconsistencies 
related to the timing of administration of trastuzumab (i.e. concurrently or sequentially).  In 
essence the authors did not compare like with like, making it difficult to draw definitive 
conclusions from the results.  Therefore trastuzumab continues to be administered for 12 
months in the adjuvant setting.  
 
4.4. Hypothesis 
Given the findings from review, we elected to determine if there is a difference in cancer-
specific outcome for patients with HER2 positive EBC treated with trastuzumab as opposed 
to those who were not treated with trastuzumab in an unselected UHL cohort. 
 
4.5. Methods and materials 
A retrospective cohort-based observation analysis was conducted.  The subgroup was 
obtained from original UHL cohort described in Chapter 2. 
 
4.5.1. Patient selection 
The subgroup under investigation involved patients diagnosed with HER2 positive EBC.  
HER2 overexpression or HER2 amplification was assessed at UHL, and if further 
confirmation was needed specimens were reviewed in central verification laboratory in 
Dublin.  HER2 positive EBC was defined as (1) a result on immunohistological analysis 
(IHC) at UHL (HercepTest, Dako Corporation) of 3+ (IHC 3+), in a range from 0 to 3+ or (2) 
positive result on fluorescence in situ hybridization (FISH) for HER2 amplification 
(PathVysion, Abbott Molecular) was required for tumours that were assessed at UHL as IHC 
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2+.  Exclusion criteria included, patients with HER2 negative EBC and metastatic disease 
(both confirmed by histologic or radiologic examination). For patients included, the 
following inclusion criteria were used: (1) patient age at presentation ≥ 18 years, (2) 
pathological data available (i.e. histologic sub-type, tumour grade of differentiation, ER 
status, PgR status, tumour size, number of lymph nodes harvested and positive nodal count), 
(3) availability of records of adjuvant systemic therapies administered, (i.e. BT, CT and HT), 
(4) availability of records of locoregional treatment (i.e. breast/axillary surgery and radiation 
administered) and, (5) follow-up conducted within Mid-Western regional cancer network or 
with listed General Practitioner (in order to obtain data on survival and recurrence).  
 
4.5.2. Data analysis 
The data was analysed as described in Chapter 2 (Section 2.3.2).   Overall survival (OS) was 
calculated as the time between the histologic diagnosis and the date of death or date of last 
contact.  Disease-free survival (DFS) was calculated as the time between histologic diagnosis 
and the date of first locoregional recurrence, first distance metastasis or death as a result of it.  
Survival curves were demonstrated using Kaplan-Meier estimates, and were compared with 
log rank analysis.  The primary comparison was done between patients who were HER2 
positive and received trastuzumab or not.  The cohort was analysed by applying descriptive 
statistics.  Two-tailed significance level was p < 0.050.  Chi-square test was used for 
categorical data. 
 
4.6. Ethics approval 
Ethics Committee approval from Ethics Committee at UHL was waived as detailed in 




4.7.1. Descriptive statistics 
147 patients with HER2 positive EBC were included.  The median follow-up was 50.2 
months.  The distribution of BT administered is shown in Table 18. It showed an increase in 
the adjuvant use of trastuzumab between the first (42.0%) and second (67.0%) halves of the 
interval examined (p = 0.001). 
 
Year of BT Adjuvant BT with Trastuzumab Offered in HER2 Positive EBC 
Yes No Not available Total 
Number Percent Number Percent Number Percent Number Percent 
2001 – 
2005 
21 42.0% 29 58.0% 0 0.0% 50 100% 
2006 – 
2010 
65 67.0% 31 32.0% 1 1.0% 97 100% 
Table 18: Summary of the distribution of trastuzumab therapy in UHL cohort. 
 
Table 19 is a summary of clinical and demographic data for UHL patients with HER2 
positive EBC.  Data is shown for all patients with HER2 positive disease, then stratified 
based on administration of BT with trastuzumab.  Comparisons were made for those who 
received trastuzumab and for those who did not.  The median age and range were comparable 
between groups.  There was a statistically significant difference in proportions for age groups 
between cohorts (p < 0.001).  The majority of patients were Caucasian across all groups.  The 
majority of patients with HER2 positive EBC were postmenopausal.  There was a statistically 






Variable All HER2 positive patients Trastuzumab cohort Non-trastuzumab cohort p value 
n (%) Median Range n (%) Median Range n (%) Median Range 
Age (years) 
 ≤ 44 years 
 45 – 54 years 
 55 – 64 years 





















































  0.002 





















  0.005 







   
22 
25 
   
13 
19 
  0.004 
Table 19: Summary of clinical and demographic data for UHL patients. 




Table 20 is a summary of the pathologic data for UHL patients with HER2 positive EBC.  
Data is shown for all patients with HER2 positive EBC, and then stratified according to 
administration of trastuzumab therapy.  The majority had ductal carcinoma across all groups.  
There was a statistically significant difference in the distribution of histologic subtypes 
between the cohorts (p < 0.001).  The greatest proportion of patients had moderately 
differentiated EBC across groups.  There was a statistically significant difference in the 
distribution of histologic grades between the cohorts (p = 0.002).  Most patients with HER2 
positive EBC had ER positive tumours.  A greater proportion of patients who did not receive 
trastuzumab were ER positive (p = 0.014).  The majority of HER positive EBC were node 







Variable All HER2 positive patients Trastuzumab cohort Non-trastuzumab cohort p value 
n (%) Median Range n (%) Median Range n (%) Median Range 
Histology 























  <0.001 
Grade
 
 I – Well 
 II – Moderate 





















































  <0.001 
Tumour size (cm)
 
 ≤ 1.00 cm 
 1.01 – 2.00 cm 













2.3 cm 0.9–9cm 0.057 
LN Stage: N0 
LN Stage:N1 (1 – 3LNs) 
LN Stage:N2 (4 – 9 LNs) 













   
<0.001 
LNR 143 0.10 0.0 – 1.0 79 0.16 0.0 – 1.0 64 0.0 0.0 – 1.0  
Table 20: Summary of pathologic data for UHL patients.  
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Table 21 is a summary of the adjuvant treatment data for UHL patients with HER2 positive 
EBC.  Data is shown for all patients with HER2 positive EBC, and then stratified according 
to administration of trastuzumab therapy. The majority had a mastectomy in all groups.  The 
majority had CT in all groups.  In patients who received trastuzumab, a higher proportion 
also received CT (p < 0.001).  Radiation was administered to a greater proportion of those 






Variable All HER2 positive patients Trastuzumab cohort Non-trastuzumab cohort p value 





















































































































































































Table 21: Summary of the adjuvant treatment data for UHL patients.   
Abbreviations:  BCS: breast-conserving surgery; ANC: axillary node clearance; ANS: axillary node sampling; SLNB: sentinel lymph node 
biopsy.  NA: not available. Univariate analysis performed.
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4.7.2. Survival analysis 
Figure 30 and 31 show Kaplan-Meier estimates for DFS and OS stratified according to 
administration of trastuzumab therapy.  There was a trend towards improved DFS (p = 0.056) 
with trastuzumab use while no such trend was seen for OS (p = 0.263).  
 
Figure 30: Shows DFS in HER2 positive EBC based on administration of trastuzumab. 
 
Figure 31: Shows OS in HER2 positive EBC based on administration of trastuzumab. 
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Figures 32, 33 and 34 show Kaplan-Meier estimates for DFS stratified by administration of 
trastuzumab therapy and also for tumour size. For tumours greater than 2.01 cm there was a 
trend for better DFS (p = 0.070). For tumours less than 2 cm no significant difference in 
outcome emerged.  
 













Figures 35, 36, and 37 show Kaplan-Meier estimates for OS stratified by administration of 
trastuzumab therapy and for tumour size.  No significant difference in outcome emerged. 
 









Figure 37:  Shows OS in HER2 positive EBC (tumour ≥ 2.01 cm) based on administration of 
trastuzumab. 
 
Figures 38 and 39 show Kaplan-Meier estimates for DFS stratified by administration of 
trastuzumab therapy and for nodal involvement.  DFS was improved for patients who 




Figure 38:  Shows DFS in HER2 positive EBC (node negative) based on administration of 
trastuzumab. 
 




Figures 40 and 41 show Kaplan-Meier estimates for OS stratified by administration of 
trastuzumab therapy and for nodal involvement.  In node positive cases there was better 
outcome for OS (p = 0.001).  
 




Figure 41:  Shows OS in HER2 positive EBC (node positive) based on administration of 
trastuzumab. 
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4.7.3. Correlation and multiple regression analysis 
Correlation and multiple regression analyses were conducted in a step-wise fashion to 
examine the relationship between OS and various predictors.  The predictors included: (1) 
age at diagnosis, (2) ECOG performance status, (3) menopausal status, (4) tumour size 
determined on pathologic assessment, (5) number of positive lymph nodes determined on 
pathologic assessment, (6) ER status, (7) PgR status, and (8) receipt of trastuzumab therapy.  












p-value Multiple regression weights 
B β p-value 
Overall survival (months) 57.4 28.8      
Age at diagnosis (years) 53.9 11.5 -0.147 0.042  - 0.145 0.081 
ECOG performance status 1 0.4 -0.093 0.136  - 0.068 0.422 
Tumour size (cm) 2.54 1.64 -0.122 0.075  - 0.104 0.216 
Number of positive lymph nodes 4 6.0 -0.063 0.228  - 0.044 0.604 
ER status 
Coded: 0: positive; 1: negative 
  -0.207 0.007 -12.506 -0.213 0.014 
PgR status 
Coded: 0: positive; 1: negative 
  -0.171 0.022  - 0.030 0.816 
Menopausal status 
Coded: 0: pre; 1: post 
  -0.119 0.080  - 0.098 0.244 
Administration of trastuzumab 
Coded: 0: yes; 1: no 
  0.170 0.022  0.141 0.094 
Table 22: Summary of statistics, correlations and results from regression analysis on OS for patients with HER2 positive EBC.   
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Correlation and multiple regression analyses were conducted to examine the relationship 
between OS in HER2 positive EBC and various potential predictors.  Table 20 summarises 
the descriptive statistics and analysis results.  Age at diagnosis, ECOG performance status, 
tumour size, number of positive lymph nodes, ER status (coded: 0: positive; 1: negative), 
PgR status (coded: 0: positive; 1: negative), and menopausal status (coded: 0: pre; 1: post) 
were negatively correlated with OS.  This indicated that (1) younger age at diagnosis, (2) 
smaller tumour size, (3) smaller number of positive lymph nodes, ER positive, PgR positive 
and premenopausal status have a longer OS. 
 
The multiple regression model with one of the eight predictors produced R
2 
= 0.043, F (1, 
138) = 797.808, p = 0.014.  As can be seen in Table 22, the ER status had a significant 
negative weight, indicating that ER positive tumours were linked with a higher OS. The 
remaining predictors did not contribute to the model.  In other words according to the 
analysis, the administration of trastuzumab was not an independent predictor of adverse or 
improved OS. 
 
4.7.4. Outcome analysis at last follow-up 
The outcome at last follow-up for subgroup (i.e. HER2 positive EBC) is shown in Figure 42.  
It shows the majority of patients (70.7%) were alive.  
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Figure 42:  Pie chart shows outcome for all HER2 positive patients. 
 
Although the outcome for subgroup chi square analysis showed no statistically significant 
difference for 5 year DFS (64% versus 53%; p = 0.123) and 5 year OS (73% versus 55%; p = 
0.103), there was a greater proportion of patients alive in the trastuzumab cohort (i.e. 80.0% 
versus 59.7%) at the end of the follow-up.  These are shown in Table 23. 
 
 Trastuzumab cohort Non-trastuzumab cohort 
Number Percentage (%) Number Percentage (%) 
Final Outcome 
Alive 
Dead: breast specific 
Dead: non-breast specific 
Dead: presumed 



























5 year DFS 














The primary objective was to determine outcome for patients with HER2 positive EBC who 
received trastuzumab and did not receive trastuzumab.  Secondary objective was to compare 
outcomes.  
 
Over the period of investigation, a change in BT practice was seen with an increased rate of 
administration of trastuzumab in patients with HER2 positive EBC (42.0% to 67.0%).  This 
followed international guidelines on treatment of HER2 positive EBC, with the adjuvant 
delivery of trastuzumab in UHL starting in mid to late 2005 (Aebi et al. 2011, Theriault et al. 
2013).  The lack of apparent concordance with HER2 positive patients receiving BT with 
trastuzumab is related to (1) favourable tumour characteristics (i.e. small tumours, node 
negative tumours and grade I tumours), (2) associated co-morbidities that preclude safe 
administration, (3) respect of patient‘s choice to decline BT and, (4) delays with availability 
of trastuzumab outside the clinical trial setting. 
 
The demographic data shows that the median age for patients with HER2 positive EBC was 
55 years.  This was lower than the 49 years reported in the HERA trial, but comparable to 
results in the PHARE trial (Piccart-Gebhart et al. 2005, Pivot et al. 2013).  The variation in 
age observed may be due to younger patients more commonly being enrolled into clinical 
trials (Aebi et al. 2011).  The greatest proportion of patients (37%) was between ages of 55 – 
64 years.  The majority (35 – 44%) in the published reports were below 49 years (Piccart-
Gebhart et al. 2005, Romond et al. 2005).  An exception was seen in the PHARE trial, where 
34% of patients were over 60 years (Pivot et al. 2013).  60% of patients were postmenopausal, 
which was higher than the 46% quoted in the HERA trial (Piccart-Gebhart et al. 2005).  This 
finding is related to the higher proportion of older patients in the UHL cohort.   
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In the present study the trastuzumab cohort had, (1) lower median age (54 years versus 57 
years), (2) higher proportion aged 55 – 64 years (43% versus 33%) (p < 0.001) and, (3) lower 
proportion of postmenopausal patients (54% versus 66%) (p = 0.002), when compared to 
non-trastuzumab cohort.  All other parameters were comparable between cohorts. The 
majority of patients were Caucasian, and this pattern was similar to the published reports 
(Piccart-Gebhart et al. 2005).  Premorbid smoking status showed that the majority of patients 
had never smoked. 
 
The pathological data showed that the majority of patients had ductal carcinoma subtype.  
55% of patients had moderately differentiated (i.e. Grade II) EBC.  This was different from 
reported data, where more poorly differentiated (i.e. Grade III) EBC was predominantly seen 
(56 – 68%) (Romond et al. 2005, Pivot et al. 2013).  The majority of patients had ER 
negative tumours (54%).  This was within the range seen in landmark trials (45 – 57%) 
(Piccart-Gebhart et al. 2005, Pivot et al. 2013).  53% of patients had PgR negative tumours.  
This was higher than range seen in the HERA and PHARE trials (37 – 42%).  In the present 
study the trastuzumab cohort had, (1) lower proportion of Grade II EBC (50% versus 61%) (p 
= 0.002), (2) lower ER positive rates (49% versus 61%) (p = 0.014) and, (3) higher PgR 
negative rates (65% versus 36%) (p < 0.001), when compared to the non-trastuzumab cohort. 
 
As was seen in most other similar studies, the majority (61%) were ≥ 2.01 cm (Piccart-
Gebhart et al. 2005, Romond et al. 2005).  An exception occurred in the PHARE trial, where 
the 55% of cases were < 2.0 cm (Pivot et al. 2013).  In the present study 39% had no lymph 
node metastases (i.e. N0 stage).  This was comparable with the HERA and PHARE cohorts, 
in which 32% and 55% were lymph node negative (Piccart-Gebhart et al. 2005, Pivot et al. 
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2013).  In other studies, higher (57%) proportion of N1 disease was noted (Romond et al. 
2005).   In this study the trastuzumab cohort had, (1) higher proportion of tumours ≥ 2.01 cm 
and, (2) lower proportion of N0 EBC (25% versus 56%) (p < 0.001), when compared to the 
non-trastuzumab cohort. 
 
The adjuvant treatment data showed the majority of patients had a mastectomy performed 
(64.6%).  This is higher than seen in published reports (57 – 63%) (Piccart-Gebhart et al. 
2005, Slamon et al. 2011).  84.4% of patients had undergone ANC.  74.8% of patients 
received CT.  For this study the trastuzumab cohort had, (1) higher proportion of mastectomy 
(67.5% versus 61.2%) (p = 0.419), (2) higher proportion of ANC (87.5% versus 80.6%) (p = 
0.041) and, (3) higher proportion of CT (95% versus 50.7%) (p = < 0.001), when compared 
to non-trastuzumab cohort.  Although the administration of BT without CT is not 
recommended in the guidelines, this was observed in a minority of cases due extenuating 
clinical circumstances (Aebi et al. 2011).  
 
55.1% of patients received HT.  Although this was slightly lower that the range seen in 
published reports (56 – 90%), it is explained by the incidence of ER and PgR positivity seen 
in the cohort (Piccart-Gebhart et al. 2005, Slamon et al. 2011).  The majority of patients 
(75.5%) had radiation administered, in keeping with the range quoted in the literature (67 – 
77%) (Piccart-Gebhart et al. 2005, Slamon et al. 2011).  In comparing the trastuzumab cohort 
with the non-trastuzumab cohort, the former had, (1) lower proportion of HT (50.0% versus 




Cancer-specific outcome was compared between the trastuzumab and non-trastuzumab 
cohorts.  On log rank analysis, DFS (p = 0.056) and not OS (p = 0.263) were improved with 
the administration of trastuzumab. This inconsistent finding might be related to the non-
randomised study design employed, as it included all patients with HER2 positive EBC 
irrespective of their fitness to undergo BT with trastuzumab.  On multivariate analysis, OS 
with administration of trastuzumab trended towards better outcome but was not statistically 
significant (p = 0.094). These results mirror those seen in published reports where 
improvements in DFS and not OS were observed (Piccart-Gebhart et al. 2005, Goldhirsch et 
al. 2013b).   On subgroup analysis, a trend towards improved outcome was observed with 
administration of trastuzumab in HER2 positive tumours ≥ 2.01 cm, for DFS (p = 0.070) and 
OS (p = 0.262).  Although some studies identified a benefit with trastuzumab in tumours > 
1.0 cm, other smaller studies have reported an absolute risk of reduction by 2 – 7% in 
tumours of any size (Piccart-Gebhart et al. 2005, Albanell et al. 2013).  Further subgroup 
analysis (using log rank to compare estimates) showed that HER2 positive tumours with 
nodal involvement had improved DFS (p < 0.001) and OS (p = 0.001).  This is supported by 
literature demonstrating a greater benefit for patients with node positive tumours receiving 
BT (Araki et al. 2012, Theriault et al. 2013).  In general, the DFS and OS indices for HER2 
positive EBC who received trastuzumab were lower than published results, however the 
present study included ‗all-comers‘ and had a greater proportion of older patients as well as 
patients with larger tumours and nodal positivity (Slamon et al. 2011, Theriault et al. 2013). 
 
4.9. Conclusions 
The aim of this Chapter was to determine and compare cancer-specific outcome in patients 
with HER2 positive EBC, based on administration of BT with trastuzumab.  Long-term 
cancer-specific outcome trended towards being improved in the cohort that received 
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trastuzumab.  The benefit was greater for HER2 positive EBC where (1) tumours ≥ 2.01 cm 
and/or (2) nodal metastases. 
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5. Chapter 5 – Impact of prognostic tools in predicting cancer-specific outcome in EBC 
 
5.1. Background 
Establishing the prognosis of a patient with EBC is a crucial step in developing an adjuvant 
treatment plan.  This may be undertaken by reviewing all the relevant clinical and pathologic 
features.  These can be combined to generate an estimate that correlates to a predetermined 
outcome (Quintyne et al. 2013).  This method is highly subjective and not always 
reproducible. 
 
Several prognostic factors have been described for EBC, but only a small proportion of these 
on further evaluation maintain independent significance on multivariate analysis (Blamey et 
al. 2007).  However, by combining significant factors, more reliable estimates may be 
produced.  This can more aptly assign patients into the appropriate risk-related grouping 
(Quintyne et al. 2010).  These groupings can help in building a therapeutic algorithm based 
on weighted risks to toxicities associated with adjuvant systemic therapies (i.e. CT and HT) 
(Campbell et al. 2010).  With greater consistency demanded in clinical practice, prognostic 
tools have begun to play greater roles as adjuncts in clinical decision-making (CDM).   
 
The Nottingham prognostic index (NPI) is one such instrument, which uses the histologic 
features of a tumour. Originally conceptualised by Blamey et al. in 1978, it was formally 
described in 1982 by Haybittle et al (Blamey et al. 1979, Haybittle et al. 1982).  It is 
calculated as follows: maximum diameter of invasive cancer size in cm x 0.2 + lymph node 
(LN) stage (1, 2 or 3) + grade of differentiation (1, 2 or 3) (Haybittle et al. 1982).  This 
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generates a score that can be correlated with a predetermined outcome.  The summary details 
of the NPI are included in Table 24 (Galea et al. 1992, Blamey et al. 2007). 
 
NPI Group NPI Score Disease-free survival (at 10 years) 
Excellent ≤ 2.40 96 % 
Good 2.42 – 3.40 93% 
Moderate 
 Moderate group 1 
 Moderate group 2 
3.42 – 5.40 
3.42 – 4.40 





 Poor group 1 
 Poor group 2 
≥ 5.42 





Table 24: Summary of information for Nottingham prognostic index risk groups and their 
associated 10- year disease-free survival figures. 
 
With the greater Internet access and use, Adjuvant! Online (AO), a free web-based tool 
(http://www.adjuvantonline.com) is increasingly used.  This instrument provides estimates 
for 10 year OS as well as potential benefits from adjuvant systemic therapies (i.e. CT and 
HT) (Ravdin et al. 2001, Olivotto et al. 2005).  AO calculates estimates based on 
combination of clinical and pathologic factors including, (1) age at diagnosis, (2) 
performance status, (3) ER status, (4) tumour grade of differentiation, (5) maximum invasive 
tumour diameter, (6) number of positive lymph nodes and, (7) proposed adjuvant systemic 
therapies (Ravdin et al. 2001, Olivotto et al. 2005, 'Adjuvant! for Breast Cancer (Version 
8.0)'  2013).   
 
AO is multidimensional incorporating both clinical and histopathologic data.   AO outputs 
four numeric values, (1) CT alone, (2) CT-HT combined, (3) HT alone and, (4) no additional 
therapy (NAT).  AO is based on an algorithm that was correlated with 10 year OS in greater 
than 30 000 female patients with EBC in the Surveillance, Epidemiology, and End Results 
(SEER) database in the United States of America (Campbell et al. 2010).  NPI and AO are 
summarised in Table 25. 
 140 
 
Variables Nottingham prognostic index Adjuvant! Online 
Population United Kingdom United States of America 
Prognostic factors Maximum tumour size 
Grade of differentiation 
Lymph node stage 
Maximum tumour size 
Grade of differentiation 
Lymph node stage 
Age at diagnosis 
ECOG performance status 
ER status 








Hormonal therapy, i.e. 
Tamoxifen ± ovarian oblation, 
aromatase inhibitors 
Survival Output Prognostic groups see Table 24 10 year predicted survival based 
on receipt of adjuvant therapy 
Additional features  Hardcopy or pdf generated for 
patient and doctor 
Table 25: Summary of NPI and AO prognostic tools.   
Abbreviations: pdf: portable document format. 
 
During the timeframe under review for the cohort, the aforementioned CDM tools (i.e. NPI 
and AO) were commonly used to assist in (1) prognostication for patients with EBC and (2) 
guidance for potential systemic therapy.  These CDM tools have become supplemented by 
gene expression profiles such as MammaPrint (Agendia, Amsterdam, The Netherlands and 
Oncotype DX Recurrence Score (Genomic Health, Redwood City, USA).   
 
MammaPrint is a 70-gene microassay that was developed based on research conducted at the 
Netherlands Cancer Institute, Amsterdam, and collaborating institutions.  It requires a fresh 
tumour sample < 7 days old and only has 1 gene in common with Oncotype DX (van de 
Vijver et al. 2002, Drukker et al. 2014).  The gene panel helps to risk-stratify breast tumours 
irrespective of ER status, into a ―low-risk‖ or ―high-risk‖ category. 
 
Oncotype DX is the first clinically validated multigene assay that is performed on RNA 
extracted from paraffin-embedded tumour tissue.  It uses a qualitative reverse transcriptase 
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polymerase chain reaction assay to evaluate the expression of 21 genes that correlate with 
breast cancer recurrence (Paik et al. 2004, Paik et al. 2006).  The results of this gene 
expression analysis in turn determine 1 of 3 recurrence score groups: low risk < 18; 
intermediate risk, 18 – 30; and high risk > 31. 
 
 
This new era of genomics has arisen, as treatment decision algorithms in breast cancer have 
become more complicated.  This is due to impact of BCMS, where more patients with lymph 
node negative EBC are being diagnosed.  However, prognostic estimates based on 
information from (1) tumour size, (2) extent of lymph node involvement and, (3) histologic 
grade as in the NPI scores, are still currently published on all UHL breast cancer pathology 
reports.  AO is also presently used in all new patient consultations in the Department of 
Medical Oncology, UHL.  AO remains limited as it does not incorporate HER2 status into its 
algorithms for estimating potential benefit from adjuvant systemic therapy.   
 
5.2. Aims 
The aims were to, (1) conduct a review of literature on NPI and AO, (2) determine and 
compare if application of these prognostics tools in UHL correlated with cancer-specific 
outcome in patients with EBC. 
 
5.3. Review of clinical trials on prognostic tools use in EBC 
5.3.1. Publication search 
Articles published from 2004 to 2014 were identified from several sources.  These included, 
(1) PubMed Central/PubMed, (2) Web of Science, (3) Google Scholar, (4) references from 
citation lists in breast cancer management guidelines (i.e. American Society of Clinical 
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Oncology (ASCO), European Society of Medical Oncology (ESMO), National 
Comprehensive Cancer Network (NCCN) and St Gallens‘.  Key words used for the search 
were, (1) Nottingham Prognostic Index (NPI), (2) Adjuvant! Online (AO), (3) prognostic 
tools, (4) adjuvant adjuncts, (5) adjuvant decision-making tools and, (6) early-stage breast 
cancer (EBC).  No limits (i.e. geographic location, participant‘s age or language) were used 
for this search.  Additionally, further reference capture was feasible by manually reviewing 
bibliographies from articles reviewed. 
 
5.3.2. Paper selection and quality assessment 
Paper selection and quality assessment were undertaken systematically.  This was done in 
comparable fashion as detailed in Chapter 3 (Section 3.3.2).  The articles reviewed are 





Figure 43: Flow-chart for NPI and AO study selection in review. 
Potentially relevant studies identified in Pub Med,  
Web of Science, Google Scholar, and guidelines from 
ASCO, ESMO, NCCN and St Gallens‘,  
n = 92 
 
Potentially relevant studies included,  
n = 52 
Potentially relevant studies included,  
n = 30 
Studies excluded because they were duplicates,  
n = 40 
Studies excluded after full abstract text reviewed,  
n = 22 
Relevant studies included in review for this thesis,  
n = 12 (7 for NPI; 5 for AO) 
 
Studies excluded after full article text reviewed, 
on the basis of not directly addressing the question,  
n = 18 
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5.3.3. Review: prognostic tools used in EBC: NPI 
The seven reviewed studies are summarised in Table 26. 
Country Cohort size Aims References 
United Kingdom 3130 To present updated survival 
figures for patients with EBC 
by NPI group. 
To compare outcomes for 
patients managed in two 
different decades. 
(Blamey et al. 2007) 
Belgium 
Validated with data 






To determine if PgR and HER2 
status in patients with EBC 
could improve NPI at 
predicting cancer-specific 
outcome. 
(Vanya Van Belle et 
al. 2010) 
Belgium 1818 To combine NPI with axillary 
staging to determine short-term 
cancer-specific outcome (i.e. 
DFS). 
(V. Van Belle et al. 
2010) 
European Union 
(EU) (10 countries) 
16944 To use NPI retrospectively to 
compare cancer-specific 
outcome in EBC in EU. 
(Blamey et al. 2010) 
Brazil, Portugal and, 
Spain 
467 To test the effectiveness of NPI 
in triple negative EBC. 
(Albergaria et al. 
2011) 
The Netherlands and 
United States of 
America 
427 To evaluate the integration of 
NPI with 70-gene signature in 
EBC to predict in node 
negative EBC. 
(Drukker et al. 2014) 
United Kingdom 1073 To test combining NPI with 
molecular features of EBC to 
predict both clinical outcome 
and relevant therapeutic 
options. 
(Rakha et al. 2014) 
Table 26: Summary of significant studies on NPI use in EBC. 
 
5.3.3.1. Blamey et al: 2007 
This was a single centre non-randomised retrospective observational study (Blamey et al. 
2007).  Patients (n = 3130) were enrolled to (1) update on short and long term cancer-specific 
outcome in the original cohort and, (2) to determine and compare NPI survival estimates in 
two separate time intervals (i.e. 1980 – 1986 and 1990 – 1999) (see Table 26).  Significant 
findings showed that breast-specific survival at 10 years was improved from 55% to 77 % for 
the respective periods. NPI indices identified an increase in the number of patients with better 
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outcome estimates, particularly in the latter cohort.   Limitations of this study included, (1) 
age restrictions for enrolment and, (2) non-randomised inclusion. 
 
5.3.3.2. Van Belle et al: 2010a 
This was a single centre retrospective observational study (Vanya Van Belle et al. 2010).  
Patients (n = 1927) were enrolled to investigate if the integration of PgR status and HER2 
status could result in an improved NPI (iNPI) performance (see Table 26).  Significant 
findings were, (1) reclassification of 20 – 30% into more appropriate risk groups, (2) 
projected survival with iNPI more accurately resembled actual survival and, (3) another 10% 
were classified into high–risk groups, where more evidence-based treatment algorithms are 
available.  Limitations with this trial included small and inadequately powered sample size.  
 
5.3.3.3. Van Belle et al: 2010b 
This was a single centre retrospective observational study (V. Van Belle et al. 2010).  
Patients (n = 1838) were enrolled to evaluate the short-term breast cancer specific DFS by 
comparing the NPI with log odds prognostic index (Lpi) (i.e., using a ratio of positive lymph 
nodes versus negative lymph nodes) (see Table 26).  The adapted formula was referred to as 
the log odds prognostic index (Lpi). Lpi and NPI estimates were then compared with no 
significance difference emerging.  The study was limited in that the survival evaluated over 
the immediate and not the long term.  
 
5.3.3.4. Blamey et al: 2010 
This was a multicentre international retrospective observational study (Blamey et al. 2010).  
NPI was determined on an independent and European wide cohort similar in scale to the 
SEER database. Prognostic profile using NPI was performed for the cohort (see Table 26).  
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Significant finding related to NPI included, (1) correlation occurred between NPI outputs 
with rank order actual survival rank order of survival, (2) a clear demarcation in actual 
survival occurred between good, intermediate and poor NPI prognostic groups, this 
demarcation was not seen between the excellent and good NPI prognostic groups and, (3) in a 
subgroup analysis a study was conducted to determine if outcome improved with CT 
administration was guided by NPI status, and there was a relative risk reduction of death of 
23% at 10 years.  Patients above 70 years were not included and patients with tumours larger 
than 4.9 cm were not included. 
 
5.3.3.5. Albergaria et al: 2011 
This was a multicentre international retrospective observational study (Albergaria et al. 2011).  
Patients (n = 467) were enrolled to test the effectiveness of NPI in stratifying EBC of 
different subtypes, especially triple-negative breast cancer (TNBC) (see Table 26).   
Significant findings included, (1) TNBC patterns of spread are comparable to luminal and 
HER2-enriched subtypes, (2) TNBC were larger and mainly Grade III and, (3) NPI 
maintained its ability to stratify and predict survival for TNBC.  The major limitation with 
this robust study design was the small cohort size. 
 
5.3.3.6. Drukker et al: 2014 
This was a multicentre prospective study led by Drukker et al. (Drukker et al. 2014).  Patients 
(n = 427) were recruited to evaluate whether adding the 70-gene signature to clinical risk 
prediction algorithms (including NPI and AO) could optimise outcome predictions and 
consequently treatment decisions in node negative EBC  (see Table 26).  After median 
follow-up of 61.1 months, the following were noted, (1) clinical risk estimations by all 
clinical algorithms improved by adding the 70-gene signature and, (2) improved 
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identification of patients with node negative EBC for whom adjuvant systemic therapy has 
limited value.  Limitations in this study were related to (1) small sample size and, (2) age and 
pathologic restrictions enforced in enrolment of patients. 
 
5.3.3.7. Rakha et al: 2014 
This was a single centre retrospective observations study led by Rakha et al. (Rakha et al. 
2014).  Patients (n = 1073) were recruited to determine if combining molecular features of 
breast cancer with established clinico-pathologic variables (i.e. NPI+) could predict both 
clinical outcome and relevant therapeutic options more accurately than existing methods (see 
Table 27).  The significant findings were, (1) seven core molecular classes were identified 
using a selective panel of 10 biomarkers, (2) incorporation of clinico-pathologic variables in 
a second-stage analysis resulted in identification of distinct prognostic groups within each 
molecular class (NPI +) and, (3) outcome analysis showed that using the bespoke NPI 
formulae for each biological breast cancer class provides improved patient outcome 
stratification superior to the traditional NPI.  Limitations included, (1) pathologic enrolment 
criteria restrictions (i.e. only T1 – T2 tumours) and, (2) non-randomised patient selection.  
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5.3.4. Review: prognostic tools used in EBC: AO 
The five reviewed studies are summarised in Table 27. 
Country (Date) Cohort size Aims References 
Canada 
(1989 – 1993) 
4083 To validate the use of AO in 
Canada. 
(Olivotto et al. 2005) 
The Netherlands 
(1987 – 1998) 
5380 To validate the use of AO in 
Dutch patients, investigating 
both its calibration and 
discriminatory accuracy. 
(Mook et al. 2009) 
United Kingdom 
(1986 -1996) 
1065 To investigate the performance 
of AO in a cohort of patients in 
the United Kingdom. 
(Campbell et al. 
2010) 
Taiwan 
(1992 – 2001) 
599 To investigate the performance 
and accuracy of AO in a cohort 
of patients in Taiwan. 
(Yao-Lung et al. 
2012) 
The Netherlands 
(1997 – 2004) 
2012 To validate the use of AO in 
older Dutch patients with EBC. 
(de Glas et al. 2014) 
Table 27: Summary of significant studies on AO use in EBC. 
 
5.3.4.1. Olivotto et al: 2005 
This was a multicentre retrospective observational study (Olivotto et al. 2005).  Patients 
(4083) were enrolled to compare 10 year observed and predicted survival in a cohort of 
patients from British Columbia Breast Cancer Outcome Unit (BCOU) database between 1989 
and 1993 (see Table 27).  The significant finding were, (1) 10 year predicted and observed 
outcomes were within 1% for OS, breast cancer-specific survival (BCSS), and event-free 
survival (EFS) (all p > 0.05), (2) observed and predicted outcomes were within 2% for most 
demographic, pathologic, and treatment-defined subgroups and, (3) AO over-estimated all 
outcome parameters for women less than 35 years (p < 0.001).  Limitations included, (1) 
enrolment restrictions in pathologic entry criteria (i.e. only tumours with T1 – 2 and N0 – 1) 
and, (2) during the period under observation, standard CT and HT use was limited. 
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5.3.4.2. Mook et al: 2009 
This was a single centre retrospective observational study (Mook et al. 2009).  Patients 
(5380) were enrolled from Netherlands Cancer Institute at the Antoni van Leeuwenhoek 
Hospital (NKI-AVL) between 1987 and 1998, to evaluate AO by investigating its calibration 
and discriminatory accuracy (see Table 27).  The significant findings were, (1) there was no 
significant difference in the 10 year observed and predicted survival (p = 0.87 and p = 0.18, 
respectively), (2) observed and predicted outcomes were within 2% for most clinical and 
pathologic subgroups, (3) AO over-estimated OS by 4.2% (p = 0.04) and BCSS by 4.7% (p = 
0.01) and (4) the concordance index (i.e. discriminatory accuracy) was 0.71 for BCSS.  
Limitations were mainly related to the standard CT and HT used (i.e. CMF and Tamoxifen 
respectively).  In keeping with this the authors recommended further evaluation in the context 
of more modern regimens. 
 
5.3.4.3. Campbell et al: 2010 
This was a single centre retrospective observational study (Campbell et al. 2010).  Patients 
(1065) were enrolled from Churchill Hospital in Oxford between 1986 and 1996, to 
investigate the performance of AO in a cohort of patients in United Kingdom (see Table 27).  
The significant findings included, (1) AO over-estimated OS (by 5.5%, p < 0.001), BCSS (by 
4.53%, p < 0.001) and EFS (by 3.51%, p < 0.001) and (2) AO over-estimated OS and BCSS 
for most demographic, pathologic and treatment-defined subgroups.  Limitations of this study 
included, (1) enrolment restrictions in pathologic entry criteria and, (2) non-randomisation of 
the selection process. 
 
 150 
5.3.4.4. Yao-Lung et al: 2012 
This was a single centre retrospective observational study (Yao-Lung et al. 2012).  Patients 
(559) were enrolled from National Cheng Kung University Hospital in Taiwan between 1992 
and 2001, to investigate the performance and accuracy of AO in cohort of Taiwanese patients  
(see Table 27).  The significant findings were, (1) significant difference in observed and 
predicted BCSS (p < 0.001), (2) in the low-risk group, there was no difference between 
observed and predicted outcome (p = 0.099) and, (3) for high-risk group, AO over-estimated 
BCSS.  Limitations arising from this study were, (1) small cohort size, (2) restrictions in 
entry criteria and, (3) period under observation, standard CT and HT used was limited. 
 
5.3.4.5. de Glas et al: 2014 
This was a multicentre retrospective observational study led by de Glas et al. (de Glas et al. 
2014).  Patients (n = 2 012) were recruited in the south-western part of The Netherlands 
between 1997 and 2004, to investigate the validity of AO in a large cohort of unselected older 
patients (see Table 27).  Data was entered from all patients with the ―average for age‖ 
comorbidity status (Model 1) and with an individualised comorbidity status (Model 2).  After 
median follow-up was 9.0 years, the significant findings were, (1) using Model 1, AO over-
estimated 10-year OS by 9.8% (95%CI: 5.9 – 13.7; p < 0.001) and 10-year cumulative 
recurrence survival by 8.7% (95%CI: 6.7 – 10.7; p < 0.001), (2) using Model 2, AO 
underestimated the 10-year OS by -17.1% (95%CI: -2.1 - -13.2; p < 0.001) and, (3) using 
Model 2, AO predicted cumulative recurrence accurately in all patients by -0.7% (95%CI: -
2.7 – 1.3; p = 0.480).  Limitations of this study included, (1) non-randomised patient 




Given the findings from reviews, we elected to determine and compare observed and 
predicted cancer-specific outcome using the NPI and AO prognostic tools in the UHL cohort. 
 
 
5.5. Methods and materials 
A retrospective observational cohort based analysis was designed.  The subgroup was 
obtained from original UHL cohort described in Chapter 2. 
 
5.5.1. Patient selection 
This subgroup under investigation involved patients diagnosed with EBC with a follow-up of 
10 years.  Exclusion criteria included, patients with less than 10 years of follow-up and 
metastatic disease (both confirmed by histologic or radiologic examination).  For patients 
included, the following eligibility criteria were used: (1) patient age at presentation ≥ 18 
years, (2) pathological data available (i.e. histologic sub-type, tumour grade of differentiation, 
ER status, HER2 status, PgR status, tumour size, number of lymph nodes harvested and 
positive nodal count), (3) availability of records of adjuvant systemic therapies administered, 
(i.e. BT, CT and HT), (4) availability of locoregional treatment (i.e. breast and axillary 
surgeries and radiation administered) and, (5) undergoing follow-up within the Mid-Western 
Regional Cancer Network or with listed General Practitioners (in order to obtain data on 
survival and recurrence). 
 
5.5.2. Data analysis 
The collected data was analysed as described in Chapter 2 (Section 2.3.2).  For each eligible 
patient, the NPI formula was used to generate the NPI score.  For each eligible patient, AO 
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standard version 8.0 was used to generate 10-year predictions for survival.  Such predictions 
were obtained by entering clinical, pathologic and proposed adjuvant treatment information.  
The AO co-morbidity window was set at default of ―minor problems‖ because,  (1) 
retrospective design of study did not allow for objectively assessing patients‘ performance 
and, (2) Canadian and United Kingdom validations studies adopted this position to ensure 
uniformity and reduce observer bias (Olivotto et al. 2005, Campbell et al. 2010). 
 
Overall survival (OS) was calculated as the time between the histologic diagnosis and the 
date of death or date of last contact.  Disease-free survival (DFS) was calculated as the time 
between histologic diagnosis and the date of first locoregional recurrence, first distance 
metastasis or death as a result of it.  Survival curves were demonstrated using Kaplan-Meier 
estimates and compared with log rank analysis.  These were used to evaluate comparative 
oncologic observed and predicted outcomes, based on NPI and AO risk stratification.  The 
cohort was analysed by applying descriptive statistics.  Two-tailed significance level was p < 
0.050.  Chi-square test was used for categorical data. 
 
5.6. Ethics approval 
Ethics Committee approval from Ethics Committee at UHL was waived as detailed in 
Chapter 2 (Section 2.4.5). 
 
5.7. Results 
5.7.1. Descriptive statistics 
171 patients with EBC were included.  The median follow-up was 121.4 months.  Table 28 is 
a summary of clinical, demographic, pathologic and adjuvant treatment data for UHL cohort.   
The median age was 54 years and age range at presentation was 23 – 87 years.  The data was 
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comparable to that presented in Chapter 2, where the largest proportion of patients were, (1) 
postmenopausal, (2) moderately differentiated tumours, (3) ductal carcinomas, (4) ER 
positive tumours, (5) PgR positive tumours, (6) HER2 negative, (7) node negative tumours, 
(8) underwent mastectomies and, (9) underwent axillary node clearances. 
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Variable Number Percentage  Median Range 














ECOG performance status 158  0 0 – 1 
Tumour size (cm)
 
  2.0 0.5 – 9.0 
Grade of differentiation
 
 I – well 
 II – moderate 














 Ductal carcinoma 
 Lobular carcinoma 
 Mixed ductal and lobular 




















































Lymph node (LN) status
 
 N0 – no LN 
 N1 – micromets or 1 – 3 LN 
 N2 – 4 – 9 LN 















Surgical intervention  
 Breast-conserving surgery 
 Mastectomy 











 Axillary node clearance 
 Axillary node sampling 
 Sentinel LN biopsy 












Table 28: Summary of clinical, pathologic and adjuvant treatment details for UHL cohort. 
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Table 29 is a summary of the UHL subgroup categorised by NPI prognostic risk group.  It 
showed the uptake of systemic therapy (i.e. CT and HT) by NPI risk groups.  It also showed 
the observed and predicted survival for the risk groups.  The majority (50.9%) were in the 
moderate NPI risk group.  Greater CT use was seen with the less favourable risk groups.  HT 
use did not exhibit a comparable pattern.  There was no significant difference between the 
observed and predicted 10-year survival for UHL cohort (p = 0.183). 
 
Table 30 is a summary of the UHL subgroup categorised by AO systemic therapy treatment 
groups.  It showed the observed and predicted survival based for the treatment groups.  The 
patients that received both CT and HT had better observed 10-year survival (69.0%).  The 
predicted survival from AO was higher than the observed survival for UHL subgroup.  This 






NPI Group Number Percentage 
(%) 
CT offered HT offered 10 year Survival 





































Incomplete 4 2.3%       
Table 29: Summary of distribution of the subgroup based on NPI. 







Variable UHL subgroup 
171 








Predicted 10 year survival (AO)  70.2% 75.7% 78.5% 68.3% 
Observed 10 year survival 66.0% 63.0% 69.0% 66.0% 33.3% 
Table 30: Summary of distribution of the subgroup based on AO treatment estimates. 
Abbreviations: UHL: University Hospital Limerick; CT: chemotherapy; HT: hormonal therapy; NAT: no additional therapy. 
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Table 31 is a summary of the CT uptake categorised by AO additional benefit indices at 10 
years.  Patients with higher AO indices were more likely to undergo adjuvant CT. 
 
AO additional benefit with CT over 10 years Chemotherapy offered 
Yes No 
 0.0 – 5.0% 
 5.1 – 10.0% 
 10.1% - 15.0% 
 ≥ 15.1% 
52/113  (46.0%) 
27/29  (93.1%) 
18/19  (94.7%) 
8/8  (100.0%) 
61/113  (54.0%) 
2/29  (6.9%) 
1/19  (5.3%) 
0/8  (0.0%) 
Missing = 2 patients   
Table 31: Summary of distribution of the subgroup based on AO benefit with CT and actual CT 
uptake.   
Abbreviations: AO: Adjuvant! Online; CT: chemotherapy. 
 
 
5.7.2. Survival analysis 
Figures 44 and 45 show Kaplan-Meier estimates for DFS and OS stratified by NPI risk 
group.  Both DFS and OS showed for better outcome in more favourable risk groups, with 
DFS (p = 0.010) and OS (p = 0.012).  
 








Figures 46 and 47 shows the Kaplan-Meier estimates stratified by AO treatment groups.  No 
significant difference was seen between the AO treatment groups in DFS (p = 0.596) curve.  
A non-significant trend towards better outcome in patients receiving HT occurred (p = 0.117).  
 
Figure 46: Shows DFS in EBC based on AO predicted outcome by treatment group. 
Abbreviations: CT: chemotherapy; HT: hormonal therapy; NAT: no additional therapy.   
 
Figure 47: Shows OS on EBC based on AO predicted outcome by treatment group. 
Abbreviations: CT: chemotherapy; HT: hormonal therapy; NAT: no additional therapy.  
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5.7.3. Correlation and multiple regression analysis 
Correlation and multiple regression analyses in step-wise fashion were conducted to examine 
the relationship between OS and various predictors.  The predictors included: (1) age at 
diagnosis, (2) ECOG performance status, (3) tumour size determined on pathologic 
assessment, (4) number of positive lymph nodes determined on pathologic assessment, (5) 
ER status, (6) PgR status, and (7) HER2 status.  Table 32 summarizes the descriptive 












p-value Multiple regression weights 
B β p-value 
Overall survival (months) 100.6 41.0      
Age at diagnosis (years) 55.1 12.1 -0.169 0.015 -0.561 -0.166 0.025 
ECOG performance status   -0.042 0.297  - 0.017 0.816 
Tumour size (cm) 2.41 1.25 -0.257 <0.001 -0.548 -0.168 0.027 
Number of positive lymph nodes 3 5.6 -0.203 0.004 -1.161 -0.166 0.025 
ER status 
Coded: 0: positive; 1: negative 
  -0.273 <0.001 -27.529 -0.284 <0.001 
PgR status 
Coded: 0: positive; 1: negative 
  -0.082 0.146  0.151 0.120 
HER2 status 
Coded: 0: positive; 1: negative 
  0.073 0.177  0.024 0.742 
Table 32: Summary of statistics, correlations and results from regression analysis of OS for patients with HER2 positive EBC in UHL cohort.   
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On univariate analysis, age at diagnosis, tumour size, number of positive lymph nodes and 
ER status were all negatively and significantly correlated with OS. PgR status and ECOG 
performance status were negatively correlated, but not significant, while HER2 status was 
positive correlated, but not significant. 
 
The multiple regression model was run in a step-wise fashion and only 4 of the 7 predictors 
formed a model and produced R
2 
= 0.182, F (4,160) = 1408.745, p < 0.001.  As can be seen in 
Table 30, age at diagnosis, tumour size, number of positive lymph nodes and ER status had 
significant negative regression weights, indicating that lower age at diagnosis, smaller tumour 
size, fewer numbers of positive lymph nodes and ER positive status was seen to have better 
OS, after controlling for the other variables in the model.  The remaining predictors did not 
contribute to the model. 
 
5.7.4. Outcome analysis at last follow-up 
The outcome for the subgroup is shown in Figure 48.  It shows the majority of patients 




Figure 48: Pie chart shows outcome for EBC in prognostic group cohort. 
 
5.8. Discussion 
The primary objective was to assess performance of prognostic tools (i.e. NPI and AO) used 
in an Irish cohort would be good predictors for cancer-specific outcome in patients with EBC. 
 
The demographic data showed that the median age for patients for the cohort was 54 years.  
This is lower than 57 – 58 years reported in the NPI trial (Vanya Van Belle et al. 2010, V. 
Van Belle et al. 2010).   
 
The pathologic data showed that the median tumour size was 2.0cm, which was comparable 
to NPI trials (1.8cm – 2.3cm) (Vanya Van Belle et al. 2010, V. Van Belle et al. 2010).  
73.7% had moderately differentiated EBC.  This was higher than seen in NPI trials (30 – 
48%) (Vanya Van Belle et al. 2010, Albergaria et al. 2011).  This was also higher than seen 
in AO trials (36 – 43%) (Olivotto et al. 2005, Mook et al. 2009).  81.9% had ductal 
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carcinoma.  This was higher than in reports for NPI trials (73%) (Blamey et al. 2010).  It was 
within the range quoted for AO trials (74 – 90%) (Olivotto et al. 2005, Mook et al. 2009). 
 
The majority (76.6%) had ER positive status, which was in the range seen in the NPI trials 
(67 – 87%) (Vanya Van Belle et al. 2010, Albergaria et al. 2011).  It was higher than seen in 
AO trials (46 – 71%) (Mook et al. 2009, Campbell et al. 2010).  A minority were HER2 
positive (8.8%), which was not comparable to NPI trials (12 – 15%) (Vanya Van Belle et al. 
2010, Albergaria et al. 2011).  This might be due to absence of mandatory HER2 testing in 
Mid-Western Ireland prior to 2005.  Greatest proportion of patients were node negative EBC 
(48.5%).  This was in the range seen for NPI trials (43 – 66%) (Blamey et al. 2010, 
Albergaria et al. 2011).  However, it was below the data seen in the AO trials (58 – 80%) 
(Mook et al. 2009, Yao-Lung et al. 2012).  This latter finding was due pathologic restrictions 
(i.e. N0 and N1 EBC only) enforced on enrolment in some of the AO trials described in 
Table 25 (Olivotto et al. 2005, Campbell et al. 2010).  57.3% of patients had undergone a 
mastectomy.  This is above quoted range for AO trials (23 – 37%) (Mook et al. 2009, 
Campbell et al. 2010).  Pathologic restrictions (i.e. tumours less than 5 cm only) in the AO 
trials might explain this finding (Olivotto et al. 2005). 
 
The distributions of the NPI categories showed that the majority were in the good-risk 
(26.9%) and moderate-risk (50.9%) groups.  This is comparable to those described in the NPI 
trials (Blamey et al. 2010).  It also noted that with increasing risk category a higher 
proportion of patients received adjuvant CT.   
 
When using the NPI, no significant differences were seen between the observed and predicted 
survival data for the UHL cohort.  The predicted survival data from AO differed from the 
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observed survival data for the UHL cohort.  There was a statistically significant difference in 
the proportions for 10-year survival between the predicted and observed results.  These 
results were comparable to that described in the validation exercise in the UK and The 
Netherlands, where it was also seen to over-estimate OS (Campbell et al. 2010, de Glas et al. 
2014). This may be due eligibility restrictions employed in the US SEER dataset used to 
generate the AO predictions (i.e. an upper age limit, upper tumour size limit and upper limit 
of nodal involvement).  The AO cohort used was not representative of true picture of EBC 
(Ravdin et al. 2001).  For the additional 10-year benefit for adjuvant CT data, it was noted 
that with increasing indices there was a greater proportion having adjuvant CT administered. 
 
The survival estimates for the cohort by NPI risk groups produced statistically significant 
distinct patterns.  These were comparable to those in reports on NPI (Blamey et al. 2007).  
This might be due to the similarities between the Irish and UK demographic.  The AO 




The aim of this Chapter was to determine and compare if the use of prognostic tools (i.e. NPI 
and AO) could be accurate predictors of cancer-specific outcome in the UHL cohort.  NPI 
consistently predicted cancer-specific outcome. AO consistently over-estimated OS.  In 
conclusion, NPI performed better than AO in the UHL cohort. 
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6. Chapter 6 – Impact of anthropometric data on cancer-specific outcome in EBC 
 
6.1. Background 
Obesity is acknowledged as a significant public health concern in developed and some 
developing countries (Flegal et al. 2010, Phillips 2013, 'WHO | Obesity'  2013).  Obesity is 
defined as a body mass index (BMI) of greater than 30kg/m
2
.  It is associated with an 
increased risk of developing cancer, as well as both cancer-specific and non-cancer specific 
morbidity and mortality (Ryan and Kushner 2010, Phillips 2013). Moreover, obesity in 
patients with EBC has poorer cancer-specific outcome when compared to non-obese 
counterparts.  The magnitude of this difference increases in the postmenopausal group 
(Chlebowski et al. 2002). 
 
There are several possible mechanisms suggested to explain the association between obesity 
with increased risk of breast cancer and these include, (1) adipose tissues increase 
endogenous oestrogens which is a known factor for FBC, (2) increased circulating levels of 
insulin and insulin-like growth factors in obese patients which can trigger carcinogenesis, (3) 
adipose tissues produce adipokines, that can stimulate or inhibit cell growth, (4) adipose cells 
may also have direct and indirect effects on other tumour growth regulators including 
mammalian target of rapamycin (mTOR) and AMP-activated protein kinase and, (5) obese 
people often have chronic low-level, or ‗sub-acute‘ inflammation that can be mutagenic 
(Iyengar et al. 2013, Ligibel and Strickler 2013).  Most studies have shown that overweight 
and obesity are associated with modest increase in risk of postmenopausal cancer (Mahoney 
et al. 2008).  This higher risk is seen mainly is women who have never used HRT and for ER 
and PgR expressing tumours.  Overweight (BMI > 25kg.m
2




obesity have, by contrast been found to be associated with a reduced risk of premenopausal 
FBC in some studies (Sparano et al. 2012).  The mechanism for this remains unclear. 
 
6.2. Aims 
The aims were to, (1) conduct a review on obesity and its association with poor cancer-
specific outcome in patients with EBC, and (2) determine and compare if premorbid 
anthropometric data influence cancer-specific outcome in the UHL cohort. 
 
6.3. Review trials anthropometric data in EBC 
6.3.1. Publication search 
Articles published from 2004 to 2014 were identified from several sources.  These included, 
(1) PubMed Central/PubMed, (2) Web of Science, (3) Google Scholar, (4) references from 
citation lists in breast cancer management guidelines (i.e. American Society of Clinical 
Oncology (ASCO), European Society of Medical Oncology (ESMO), National 
Comprehensive Cancer Network (NCCN) and St Gallens‘.  Key words used for the search 
were, (1) Body Mass Index (BMI), (2) obesity and, (3) early-stage breast cancer (EBC).  No 
limits (i.e. geographic location, participant‘s age or language) were used for this search.  
Additionally, further capture of references was feasible by manually reviewing bibliographies 
from articles reviewed. 
  
6.3.2. Paper selection and quality assessment 
Paper selection and quality assessment were undertaken systematically.  This was done is 
comparable fashion as detailed in Chapter 3 (Section 3.3.2).  The articles reviewed are 





Figure 49: Flow-chart for premorbid obesity study selection. 
Potentially relevant studies identified in Pub Med,  
Web of Science, Google Scholar, and guidelines from 
ASCO, ESMO, NCCN and St Gallens‘,  
n = 176 
 
Potentially relevant studies included,  
n = 60 
Potentially relevant studies included,  
n = 26 
Studies excluded because they were duplicates,  
n = 116 
Studies excluded after full abstract text reviewed,  
n = 34 
Relevant studies included in review for this thesis,  
n = 9 
 
Studies excluded after full article text reviewed, 
on the basis of not directly addressing the question,  
n = 17 
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6.3.3. Review: premorbid obesity in patients with EBC 
The nine reviewed studies are summarised in Table 33. 





282137 To determine risk of cancer 
associated with > 5kg/m
2
 
increase in BMI. 







424168 To determine the effect of 
obesity on survival in newly 
diagnosed EBC. 
(Protani et al. 2010) 
Denmark 53816 To determine impact of obesity 
on EBC recurrence and death. 
(Ewertz et al. 2011) 
North America 4950 To correlate BMI to cancer-
specific outcome in hormone 
receptor-positive EBC. 
(Sparano et al. 2012) 
North America  To determine impact on obesity 
on race-specific breast cancer 
incidence and mortality. 
(Chang et al. 2012) 
North America 485 To determine the impact of 
BMI and EBC recurrence, 
breast cancer-specific mortality 
and all-cause mortality. 
(Kamineni et al. 
2013) 
North America 11351 To determine association 
between BMI and ethnicity in 
newly diagnosed EBC. 
(Kwan et al. 2014) 
North America 6342 To determine relationship 
between obesity, diabetes and 
survival outcome in EBC. 
(Jiralerspong et al. 
2013) 
France  4996 To examine impact baseline 
BMI on DFS and OS in EBC 
(Ladoire et al. 2014) 
Table 33: Summary of studies on premorbid obesity in EBC. 
 
 
6.3.3.1. Renehan et al.: 2008 
This was a systematic review and meta-analysis (Renehan et al. 2008).  Patients (n = 282137) 
were enrolled to (1) assess the strength of associations of BMI and different cancer types and, 
(2) to investigate differences in the association of gender and ethnic groups (see Table 33).  
Significant findings included, (1) weak positive association between (RR < 1.20) between 
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increased BMI and postmenopausal breast cancer and, (2) strong associations in Asia-Pacific 
populations between increased BMI and premenopausal (p = 0.009) and postmenopausal 
(p=0.06) breast cancer.  Limitations of this study included, (1) the study was not strictly 
confined to reviewing obesity and breast cancer and, (2) lack of precision in measuring 
individual confounding factors such as smoking status. 
 
6.3.3.2. Protani et al.: 2010 
This was a systematic review and meta-analysis (Protani et al. 2010).  Patients (n= 424168) 
were enrolled to investigate the effect of obesity on survival of women with breast cancer.  
Significant findings included, poorer overall survival (HR, 1.33; 95%CI: 1.21 to 1.47) and 
breast cancer-specific survival (HR, 1.33; 95%CI: 1.19 to 1.50).  This study was limited by 
the heterogeneity of the cohort. 
 
6.3.3.3. Ewertz et al.: 2011 
This was a retrospective observational study (Ewertz et al. 2011).  Patients (n = 53816) were 
enrolled to characterise the impact of obesity on the risk of breast cancer recurrence and 
death as a result of breast cancer or other causes in relation to adjuvant therapy.  Significant 
findings for patients with BMI of 30kg/m
2
 or more compared to patients with BMI of 
25kg/m
2
 were, (1) older age and disease was more advanced at presentation (p = 0.001), (2) 
increased risk (by at least 46%) of developing distant metastases after 10 years and, (3) long 
term risk of dying as result of breast cancer was significantly increased by 38%.  Limitations 
of this study included, (1) lack of complete information on how BMI details were collected 
and, (2) data validation steps not included in the protocol. 
 
 171 
6.3.3.4. Sparano et al.: 2012 
This was a retrospective observational study (Sparano et al. 2012).  Patients (n = 4950) were 
enrolled to investigate if obesity at diagnosis was associated with inferior outcomes in 
hormone receptor-positive operable breast cancer.  Significant findings included, (1) 
increasing BMI (evaluated as a continuous variable) was associated with inferior outcomes in 
hormone receptor-positive, HER2 negative EBC for DFS (p = 0.008) and OS (p = 0.007) and, 
(2) increasing BMI (evaluated as a categorical variable) was associated with inferior DFS 
(HR, 1.24; 95%CI: 1.06 to 1.46; p = 0.008) and OS (HR, 1.37; 95%CI: 1.13 to 1.67; p = 
0.002).  Limiting this study was the lack of heterogeneity given that patients with ER 
negative were not included. 
 
6.3.3.5. Haakinson et al.: 2012 
This was a retrospective observational study (Haakinson et al. 2012).  Patients (n = 1352) 
were enrolled to investigate the impact of obesity on clinical presentation, tumour 
characteristics and survival outcomes in patients with breast cancer.  Significant findings for 
obese patients compared to non-obese patients were, (1) they formed a greater proportion of 
patients diagnosed over the age of 50 years (82% vs. 18%, p = 0.0019), (2) were more likely 
to have screen-detected breast cancer (67% vs. 56%, p = 0.0006), (3) had larger tumours at 
presentation (1.7 cm vs. 1.4 cm, p < 0.001) and, (4) had higher rates of lymph node 
metastases (31% vs. 25%, p = 0.026).  Limitations of this study included, (1) small cohort 
size and, (2) lack of ethnic diversity. 
 
6.3.3.6. Chang et al.: 2012 
This was a simulation model observational study (Chang et al. 2012).  National data was 
utilised relating to multiple birth cohorts in United States of America (USA).  Outcome 
 172 
parameters were affected by obesity (BMI of ≥ 30kg/m
2
) in conjunction with its age-, race-, 
cohort-, and, time-period-specific prevalence.  This permitted for the generation of age-
standardised breast cancer incidence and mortality cases and, including deaths attributable to 
obesity.  Significant findings included, (1) obesity is more prevalent among Blacks than 
Caucasians up to age 74 years, when the relationship reverses, (2) the model estimated that 
the fraction of USA breast cancer cases attributable to obesity is 3.9 – 4.5% for Caucasians 
and 2.5 – 3.6% for Blacks and, (3) obesity accounts for 4.4 – 9.2% and 3.1 – 8.4% of total 
number of breast cancer deaths in Caucasians and Blacks respectively.  A limitation of this 
study was the application of a non-validated experimental approach. 
 
6.3.3.7. Kamineni et al.: 2013 
This was a retrospective observational study (Kamineni et al. 2013).  Patients (n = 485) were 
enrolled to examine the association between BMI and risk of breast cancer recurrence, breast 
cancer-specific mortality, and all-cause mortality, and evaluated whether tumour 
characteristics differ by BMI among a mammographically screen population with access to 
treatment.  Significant findings for obese women (within 10 years of diagnosis) were, (1) 
increased risk of recurrence (HR, 2.43; 95%CI: 1.34 to 4.41) and, (2) increased breast cancer 
death (HR, 2.41; 95%CI: 1.00 to 5.81).  Limitations were related to restrictions on 
recruitment, which included, (1) lower age limit of 40 years, (2) Stage I and II EBC only and, 
(3) use of mammographically screened population only. 
 
6.3.3.8. Kwan et al.: 2014 
This was a retrospective observational study (Kwan et al. 2014).  Patients (n = 11351) were 
enrolled from the California Cancer Registry between 1993 and 2007, to investigate body 




) was associated with increased risk of breast cancer mortality compared with 
being normal weight in non-Latina whites (HR= 1.91; 95%CI: 1.14 to 3.20), (2) in Latinas, 
only morbid obese (BMI ≥ 40kg/m
2
) were at high risk of death (HR = 2.26; 95%CI: 1.23 to 
4.15) and, (3) no BMI-mortality associations were apparent in African Americans and Asian 
Americans.  A limitation of this study was related to its reliance on self-reporting of height 
and weight in cohort for the calculation of BMI. 
 
6.3.3.9. Jiralerspong et al.: 2013 
This was a retrospective observational study (Jiralerspong et al. 2013).  Patients (n = 6342) 
were enrolled to determine the relationship between obesity, diabetes and survival in a cohort 
of breast cancer patients receiving current oncologic regimens.  Significant findings relative 
to normal weight women, showed that hazard ratios for recurrence-free survival (RFS), OS 
and, breast cancer-specific survival (BCSS) for (1) overweight women were 1.18 (95%CI: 
1.02 to 1.36), 1.20 (95%CI: 1.00 to 1.42) and, 1.21 (95%CI: 0.98 to 1.48), (2) obese women 
were 1.13 (95%CI: 0.98 to 1.31), 1.24 (95%CI: 1.04 to 1.48) and, 1.23 (95%CI: 1.00 to 1.52) 
and, (3) subset analysis showed these differences were significant for ER positive EBC, but 
not ER negative or HER2 positive EBC.  Limitations of this study included, (1) heterogeneity 
population of cohort and treatments utilised and, (2) lack of data on systemic therapies used 
and relative impact on outcome. 
 
6.3.3.10. Ladoire et al.: 2014 
This was a retrospective observational study (Ladoire et al. 2014).  Patients (n = 4996) were 
enrolled to examine the association between baseline BMI, DFS and OS in EBC.  Significant 
findings included, (1) obese patients present at a more advanced stage compared to non-obese 
patients and, (2) obesity was moderately associated with poorer DFS (HR, 1.18; 95%CI: 1.01 
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to 1.39; p = 0.04), and poorer OS (HR, 1.38: 95%CI: 1.13 to 1.69; p = 0.002).  This study 
excluded patients with node negative EBC which was a limitation. 
 
6.4. Hypothesis 
Given the findings from the review, we elected to determine if premorbid obesity (based on 
BMI) was associated with less favourable cancer-specific outcome for patients with EBC. 
 
6.5. Methods and materials 
A retrospective cohort-based observation study was designed.  The subgroup was obtained 
from original UHL cohort described in Chapter 2.  
 
6.5.1. Patient selection 
This subgroup under investigation involved patients diagnosed with EBC who had 
anthropometric data available.  Exclusion criteria included, patients with metastatic disease 
(confirmed by either histopathologic or radiologic examination). Inclusion criteria included: 
(1) patient age at presentation ≥ 18 years; pathological data available, (2) pathological data 
available (i.e. histologic sub-type, tumour grade of differentiation, ER status, HER2 status, 
PgR status, tumour size, number of lymph nodes harvested and positive nodal count), (3) 
availability of records of adjuvant systemic therapies administered (i.e. BT, CT and HT used), 
(4) availability of record of locoregional treatment (i.e. breast and axillary surgeries and 
radiation administered) and, (5) undergoing follow-up within the Mid-Western Regional 




6.5.2. Data analysis 
For each eligible patient, BMI was calculated using formula [Weight (kg)/Height squared 
(m
2
)] (Keys et al. 1972).  The collected data was analysed as described in Chapter 2 
(Section 2.3.2). Overall survival (OS) was calculated as the time between the histologic 
diagnosis and the date of death or date of last contact.  Disease-free survival (DFS) was 
calculated as the time between histologic diagnosis and the date of first locoregional 
recurrence, first distance metastasis or death as a result of it.  Non cancer-specific survival 
(NCSS) was calculated as the time between histologic diagnosis and date of death from any 
non-cancer cause.  Survival curves were demonstrated using Kaplan-Meier estimates and 
compared with log rank analysis.  These were used to evaluate comparative cancer-specific 
outcomes in EBC, based on BMI category.  The cohort was analysed by applying descriptive 
statistics.  Two-tailed significance level was p < 0.050.  Chi-square test was used for 
categorical data. 
 
6.5.3. Ethical approval 
Ethics Committee approval from Ethics Committee at UHL was waived as detailed in 
Chapter 2 (Section 2.4.5). 
 
6.6. Results 
6.6.1. Descriptive statistics 
827 patients with EBC with BMI data were included.  The median follow-up was 55.8 
months.  The median age at diagnosis was 54.0 years (Range: 25 – 82 years).  The median 
BMI was 27.1 kg/m
2
 (Range: 15.7 – 53.3 kg/m
2
) and the distribution for subgroup is shown 
in Figure 50, where by underweight BMI: < 18.5kg/m
2




overweight: 25.1 – 30.0 kg/m
2
; and obese: > 30kg/m
2
 (Ryan and Kushner 2010, 'WHO | 
Obesity'  2013).   
 
Figure 50: Pie chart demonstrating distribution of patients in BMI categories (i.e. underweight, 
normal, overweight and obese) for patients with EBC. 
 
The BMI distribution over the period is shown in Figure 51. A non-significant increase in 
obesity occurred from 2000 to 2004 ((17% to 28%, p = 0.534), after which the distribution 
remained largely unchanged until 2010.   
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Figure 51: Shows the change in BMI categories (i.e. underweight, normal, overweight and 
obese) for the period of study. 
 
Table 34 is a summary of clinical and demographic data for UHL patients for whom BMI 
data is available.  Comparisons were made between groups with normal BMI and obese BMI.  
The median age was greater in obese group than normal group.  Most normal BMI patients 
occurred within the ≤ 44 years cohort.  The greatest proportion of obese BMI patients 
occurred within the 55 – 64 years.  In general the median age for patients with obese BMI 
was greater than those with normal BMI (i.e. 57 years versus 51 years, p < 0.001).  Majority 
of patients in all groups were Caucasian.  Whilst most patients were postmenopausal, there 
was an equal distribution of menopausal status in normal BMI patients.  There was a higher 






Variable Body mass index (BMI) categories p 
value Underweight Normal Overweight Obese 
Number Median Range Number Median Range Number Median Range Number Median Range 
Age (years) 
 ≤ 44 years 
 45 – 54 years 
 55 – 64 years 































































  <0.001 


























  <0.001 
Family history of cancer 
 Breast/ovarian 




   
70 
83 
   
80 
105 
   
53 
87 





















  0.225 
Table 34: Summary of clinical and demographic data stratified by BMI category for UHL patients.  
Abbreviations: NA: not available; PS: performance status.  p value calculated by comparing normal BMI versus obese BMI. Univariate analysis performed. 
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Table 35 is a summary of the pathologic information for UHL patients with BMI data.  Data 
is shown for patients with EBC by BMI category.  Comparisons were made for those with 
normal BMI and those with obese BMI.  The majority had ductal carcinoma in all groups.  
The greatest proportion of patients had  (1) moderately differentiated EBC, (2) positive ER 
status and, (3) negative HER2 status across all groups.  There was a higher proportion of 
patients with HER2 positive status in normal BMI group compared to obese BMI group (p=  
0.007). Tumours in the obese group were significantly larger in normal BMI group (2.50 cm 






Variable Body mass index (BMI) categories p 
value Underweight Normal Overweight Obese 
Number Median Range Number Median Range Number Median Range Number Median Range 
Histology 
 Ductal carcinoma 























  0.079 
Grade of differentiation 
 I – Well 
 II – Moderate 





























  269 
195 
74 
  323 
222 
101 
  227 
177 
50 







  198 
54 
144 
  234 
52 
182 
  174 
30 
144 
  0.007 
Tumour size (cm) 
 ≤ 1.00 cm 
 1.01 – 2.00cm 

















2.50 0.0 – 10 0.005 
LN stage, 
 N0, N0 (itc+) 
 N1, N1mi (1-3LNs) 
 N2 (4 – 9 LNs) 





















  0.172 
LNR 8 0.00 0 – 1 265 0.04 0 – 1 321 0.07 0 – 1 223 0.06 0 – 1  
Table 35: Summary pathological data stratified by BMI category for UHL patients.   
 p value calculated by comparing normal BMI versus obese BMI.  Univariate analysis performed. 
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Table 36 is a summary of the pathologic information for UHL patients with BMI data.  Data 
is shown for patients with EBC by BMI category. The majority had a mastectomy as 
definitive surgery in all groups.  Most patients in all groups had CT and HT.  A minority of 






Variable Body mass index (BMI) categories p value 
Underweight Normal Overweight Obese 





















































































































































































































Table 36: Summary of the adjuvant treatment data stratified by BMI category for UHL patients.  
Abbreviations: BCS: breast conserving surgery; O&D – Offered and declined; NA: not available.  p value calculated by comparing normal BMI versus obese 
BMI.  Univariate analysis. 
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6.6.2. Survival analysis 
Figures 52, 53, and 54 show the Kaplan-Meier estimates for DFS, OS and NCSS stratified 
by BMI category.  DFS (p = 0.691) and OS (p = 0.301) estimates were not altered by 
anthropometric status.  There was a trend for NCSS in obese BMI group (p = 0.051). 
 
Figure 52: Shows DFS by BMI category in UHL patients. 
 
Figure 53: Shows OS by BMI category in UHL patients. 
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Figure 54: Shows NCSS by BMI category in UHL patients. 
 
Figures 55, 56, and 57 show Kaplan-Meier estimates for DFS, OS and NCSS stratified by 
BMI category, but excluding the underweight category, as this included 8 patients only for 
whom there were no recordable events.  The DFS (p = 0.916) and OS (p = 0.411) estimates 
do not show a difference in cancer-specific outcome by BMI category.  There was a 
significant trend for poorer outcome in obese BMI category for NCSS (p = 0.024).  
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Figure 55: Shows DFS by BMI category without underweight in UHL patients. 
 
Figure 56:  Shows OS by BMI category without underweight in UHL patients. 
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Figure 57: Shows NCSS by BMI category without underweight in UHL patients. 
 
6.6.3. Correlation and multiple regression analysis 
Correlation and multiple regression analyses were conducted in a step-wise fashion to 
examine the relationship between OS and various predictors.  Predictors included, (1) age at 
diagnosis, (2) ECOG performance status, (3) menopausal status, (4) BMI category, (5) 
tumour size determined on pathologic assessment, (6) number of positive lymph nodes 
determined on pathologic assessment, (7) ER status, (8) PgR status, and (9) HER2 status.  











p-value Multiple regression weights 
B β p-value 
Overall survival (months)        
Age at diagnosis (years)   -0.169 <0.001 -0.485 -0.170 <0.001 
ECOG performance status   -0.020 0.283  0.008 0.813 
Tumour size (cm)   -0.065 0.032  - 0.055 0.112 
Number of positive lymph nodes   -0.053 0.065  - 0.031 0.381 
Body mass index (BMI)   -0.049 0.082  - 0.030 0.396 
ER status 
Coded: 0: positive; 1: negative 
  -0.088 0.006 -5.441 -0.077 -0.028 
PgR status 
Coded: 0: positive; 1: negative 
  -0.060 0.045  0.015 0.753 
HER2 status 
Coded: 0: positive; 1: negative 
  0.082 0.010 5.964 0.070 0.045 
Menopausal status 
Coded: 0: pre; 1: post 
  -0.135 <0.001  - 0.003 0.950 
Table 37: Summary of statistics, correlations and results from regression analysis of OS by BMI category in UHL patients. 
Abbreviations: ECOG: Eastern Cooperative Oncology Group; ER: oestrogen receptor; PgR: progesterone receptor. 
 
 188 
On univariate analysis, age at diagnosis, tumour size, ER status, PgR status, and menopausal 
status were negatively and significantly correlated with OS.  HER2 status was positively and 
significantly correlated.  The remainder of the predictors were negatively but not significantly 
correlated.   
 
The multiple regression model with two of the nine predictors produced R
2 
= 0.041, F(3,804) 
= 941.862, p < 0.001.  As can be seen in Table 37, the ER positive status had significant 
negative weight, and HER2 negative status had a significant positive weight, after controlling 
for other predictors in the model, and consequently all can impact on OS.  The remaining 
predictors did not contribute to the model. 
 
6.6.4. Outcome at last follow-up 
Figure 58 shows the summary outcome for this subgroup of 827 patients, with 76% being 
alive. 
 




The primary objective was to determine if premorbid BMI in EBC could affect cancer-
specific outcome in UHL cohort. 
 
Over the period of investigation, a change in BMI categories was seen with increases in the 
obese category of patients (16.7% to 27.7%).  This was in keeping with the patterns seen in 
national and international figures ('WHO | Obesity'  2013). 
 
Clinical and demographic data for BMI categories were reviewed and the majority of 
parameters were comparable.  Patients with obese BMI presented at significantly older ages 
than patients with normal BMI.  This was expected, as the incidence of obesity is greater in 
older populations ('WHO | Obesity'  2013).  A greater proportion of obese patients presented 
via the BCMS programs.  This finding was expected given that patients with larger body 
habitus have an associated large breast cup-size, which reduces the likelihood of lesion 
detection on self-breast assessment (Jiralerspong et al. 2013). 
 
Pathologic data was mainly similar for BMI categories.  However exceptions in patients with 
obese BMI where, (1) tumours were larger at presentation and, (2) had a greater degree of 
nodal involvement.  Notwithstanding these findings, the adjuvant treatment information was 
identical between groups.  
 
Despite the differences detailed above, DFS and OS were not altered by anthropometric 
status.  This finding was unexpected in particular given increases in tumour size and nodal 
involvement in the obese BMI group.  The findings can however be partially explained by the 
similarities in oncologic treatments across all groups. It has however shown that BMI 
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category did impact on non-cancer-specific outcome.   As expected NCSS was diminished in 
the obese BMI group.  This finding is in keeping with published reports (Sparano et al. 2012, 
Ligibel and Strickler 2013). 
 
6.8. Conclusions 
In the UHL cohort, anthropometric status did not predict adverse DFS and OS.  Obese BMI 
was associated with adverse NCSS. 
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7. Chapter 7 – Conclusions and Recommendations 
7.1. Context 
This study aimed to determine outcomes associated with the introduction of taxanes and 
trastuzumab, in adjuvant treatment algorithms for patients with EBC in UHL.  It aimed to 
determine if use of prognostic tools (i.e. NPI and AO) and premorbid factors (i.e. BMI) could 
predict cancer-specific outcome for patients with EBC in UHL.  The study was partly 
prompted by the lack of similar data on cohorts indigenous to Ireland.  The specific questions 
addressed were: 
1. Are patients with EBC in UHL comparable as a cohort to international cohorts with a 
similar diagnosis? 
2. What is the outcome for patients with node positive EBC in UHL and who receive 
adjuvant taxane CT? 
3. What is the outcome for patients with HER2 positive EBC in UHL and who receive 
adjuvant trastuzumab? 
4. Is there a correlation between prognostication utilising NPI and AO and cancer-
specific outcome? 
5. Is there a correlation between premorbid anthropometric data and cancer specific 
outcome? 
 
7.2. Main findings 
The main findings are summarised as follows: 
 Significant differences were noted between the Mid-Western UHL cohort and 
international cohorts.  In particular, rates of adverse features were higher in the Mid-
Western UHL cohort. 
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 The use of adjuvant taxane-based CT was not associated with improved cancer-
specific outcome in node positive EBC.  However, administration of third-generation 
taxane-based CT was associated with improved cancer-specific outcomes when 
compared with second-generation taxane and non-taxane based CT. 
 There was a trend for better DFS in HER2 positive EBC with use of adjuvant 
trastuzumab. 
 A correlation was noted between actual cancer-specific outcome as per 
prognostication with NPI, but not with AO. 
 Premorbid anthropometric data accurately prognosticated non-cancer specific survival, 
but not cancer-specific survival. 
 
7.3. Significance of findings 
7.3.1. Are patients with EBC in UHL comparable as a cohort to international 
cohorts with a similar diagnosis? 
In comparing patients diagnosed with EBC in the Mid-Western region of Ireland with 
international cohorts multiple demographic differences emerged: patients in the Irish cohort 
had lower age at presentation, higher rates of smoking, higher levels of ER positivity and, 
higher levels of nodal metastases.  Epidemiological data demonstrates that smoking is 
strongly associated with development of cancer and other chronic illnesses ('WHO | 
Publications - Global Tobacco Epidemic'  2013).  This may explain the increased 
presentation at younger ages in the Irish cohort from UHL.  This is significant, as 
participation in screen-detection programs is predicated on patients reaching a particular age.  
Most of the cancers included were not screen detected, which could account for the increased 
incidence of nodal metastases.  Data indicates that nodal spread is less common in patients 
with screen-detected malignancy ('WHO | Breast cancer: prevention and control'  2012).  In 
 193 
addition there were higher rates of administration of CT, HT and radiation, which is likely 
accounted for by increased presence of adverse features in the Irish cohort. 
 
During the period examined an expected trend towards greater application of breast 
conserving surgery occurred (i.e. BCS and SLNB).  This coincided with the introduction of 
enhanced breast surgical services (employing the latest oncoplastic techniques) in the Mid-
Western region, in 2005.  Nationally, BCMS was introduced in 2007, which additionally led 
to increases in screen-detected malignancy (i.e. more amenable to breast conserving surgical 
approaches).  The combination of increased breast conserving techniques (i.e. BCS and 
SLNB) and increased incidence of nodal metastases, partially explains the increased 
utilisation of radiotherapy in the Irish cohort.  
 
7.3.2. What is the outcome for patients with node positive EBC in UHL who 
receive adjuvant taxane CT? 
The general use of taxane-based CT was not associated with improved cancer-specific 
outcomes (Henderson et al. 2003, Chu et al. 2006). Improvements were noted with the third 
generation taxanes, compared with earlier generations.  Second generation taxanes had 
similar outcomes to those observed with non-taxane based regimens.  Importantly, all 
generations of taxane CT was associated with better disease-specific outcome when the 
analysis was confined to patients with HER2 positive EBC.  This finding may be explained 
by a synergism between taxanes and trastuzumab therapy.  
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7.3.3. What is the outcome for patients with HER2 positive EBC in UHL who 
receive adjuvant trastuzumab? 
The introduction of adjuvant trastuzumab therapy in HER2 positive EBC was associated with 
improved cancer-specific outcome.  This is supported by the general literature (Piccart-
Gebhart et al. 2005, Slamon et al. 2011).  The findings reinforce the benefits associated with 
integration of targeted biological therapies in adjuvant regimens.  The benefit was most 
apparent in patients with HER2 positive EBC who had larger tumours and nodal involvement.   
 
7.3.4. Is there a correlation between prognostication utilising NPI and AO and 
cancer-specific outcome? 
Prognostication using the NPI instrument correlated better with actual outcome compared 
with that using the AO instrument.  This may be explained by strong similarities between the 
UHL cohort and the cohort originally utilised to generate the NPI in the first instance.  These 
included comparable demographic and pathologic features between the two cohorts.  In 
addition, both studies were based on single centre experiences.   
 
Discordance was seen with prognostication using the AO instrument and actual outcome in 
the UHL cohort.  This may be due to differences in demographic features (i.e. greater ethnic 
diversity in SEER database) and restrictions in inclusion criteria of demographic information  
(i.e. upper age limit) and pathologic information (i.e. upper tumour size limit of 5.0cm and 
upper lymph node involvement limit of 3) in AO extraction from SEER database (Ravdin et 
al. 2001).    
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7.3.5. Is there a correlation between premorbid anthropometric data and 
cancer-specific outcome? 
Not in keeping in the general literature, premorbid anthropometric status did not correlate 
with cancer-specific outcome for patients in UHL with EBC.  It did however correlate with 
adverse non-cancer specific outcome.  This finding highlights the relationship between 
obesity and non-cancer specific co-morbidities.  On subgroup analysis of obese patients with 
EBC, and in keeping with published findings, it was noted that patients were older, more 
likely to have screen-detected disease, have larger tumours and have nodal metastases 
(Ewertz et al. 2011, Haakinson et al. 2012). 
 
7.4. Implications for service provision 
For patients with node positive EBC and HER2 positive EBC in the Mid-Western region, the 
introduction of new treatments (i.e. taxanes and trastuzumab respectively) led to improved 
outcomes.  Importantly, the findings support the continued usage of these components in 
adjuvant regimens.  In addition, the use of prognostic instruments (i.e. NPI and AO) 
differentially aided in prognostication, i.e. the NPI correlated best with actual outcome.  
Hence increased application of the NPI may be more appropriate in this region.  Finally, 
premorbid BMI status better identified patients at increased risk of non-cancer related 
morbidities. 
 
7.5. Recommendations for future research 
Taxane CT has cancer-specific benefits in node positive EBC.  However, evaluation of its use 
in high-risk node negative EBC would be beneficial, as this subgroup is associated with 
increased risk of relapse.  The benefits of targeted therapy with trastuzumab were 
demonstrated.  Further evaluation of the clinical benefits in specific HER2 positive EBC 
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subgroups (i.e. small tumours, node negative tumours and elderly patients) is warranted.  
Prognostication is an important adjunct to clinical practice.  The findings demonstrate that 
international instruments have differential accuracy in the Irish context.  As a result, there is 
pressing need to generate instruments that are ideally suited to the Irish breast cancer patient 
context.  Similarly, other prognostic instruments (i.e. Oncotype Dx) could be utilised in 
future studies on the present cohort.  It is likely, though not certain, that improvements in 
cancer-specific outcome led to overall improvements in quality of life.  Given the potential 
adverse side effects of adjuvant treatment modalities future studies should address quality of 
life of patients in the cohort investigated. 
 
7.6. Limitations 
A number of weaknesses limit the study conclusions as follows.  Due to the heterogeneous 
source of patient data, a considerable length of time was spent in data collection.  This is 
associated with increased risks of uneven follow-up or loss to follow-up.  To counter these 
limitations a comprehensive electronic patient record was generated for each patient.  A 
second limitation related to the single site nature of the study.  This is associated with non-
randomised patient selection, lack of adequate case mix and diversity in management 
strategies.  These weaknesses were partially overcome in 2006 when UL as designated one of 
the eight cancer centres for delivery of cancer care in Ireland.  This has led to an increase in 
staffing levels in breast cancer services.  It ensured that patients within the Mid-Western 
region received a uniform standard of care.  A further weakness related to small numbers in 
the subgroups analysed.  This limits the number of conclusions that can be drawn.  Against 
this however, were that findings generated were similar to those observed in international 
series.  A fourth limitation related to the lack of qualitative data.  For example, it was not 
possible to determine if changes in adjuvant treatment algorithms led to overall 
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improvements in patient quality of life.  This represents a further avenue for future research 
in this cohort. 
 
7.7. Conclusions 
 Differences occurred in demographic characteristics and pathologic properties in the 
UHL EBC cohort, when compared with international cohorts. 
 Cancer-specific outcome was improved in patients with node positive EBC who 
received third-generation taxane CT when compared to non-taxane CT. 
 Cancer-specific outcome trended towards being improved in patients with HER2 
positive EBC who received trastuzumab therapy when compared to no trastuzumab 
therapy. 
 Prognostic tools were useful in clinical practice, but NPI performed better than AO in 
the UHL cohort. 
 Premorbid anthropometric data did not predict cancer-specific outcome in patients 
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Background 
The number of involved axillary lymph nodes (LNs) found on pathological assessment is regarded as a significant prognostic 
factor for patients with early-stage breast cancer (EBC).  Recent reports have suggested that LNR may be a better surrogate 
at predicting cancer-specific outcome than the number of involved LN.  This retrospective study investigated the prognostic 
value of LNR, using earlier published cut-off values, before the introduction of SLNB. 
 
Methods and materials 
A population-based study was performed, using data from UHL Oncology Database, including all women diagnosed with 
node-positive EBC between 01/01/2001 and 31/12/2010 (N=553).  Records were retrospectively evaluated for clinical, 
demographic and pathologic data.  Majority had axillary node clearance (ANC) (548/553; 99.1%).  Patients were divided 
into 3 LNR risk groups (Low: ≤ 0.20; Intermediate: 0.21 – 0.65; and High: > 0.65).  Kaplan-Meier survival analysis was 




Median follow-up: 59.8 months (IQR: 37.1 – 88.9).  LNR distribution: Low: 303/553 (54.8%), Intermediate: 160/553 
(28.9%) and, High: 90/553 (16.3%).  Kaplan-Meier estimates for OS stratified by LNR risk group, showed Low risk group 
had better outcome for OS (p < 0.001) (see Figure 1).  
 
 
Figure 1: Shows OS in node-positive EBC based on LNR risk group. 
 
 
5- and 10-year OS survival rates were 63% and 58%, respectively.  The number of positive LNs correlated with 10-year OS 
(66%, 48% and, 48% for patients with N1, N2 and N3 stage respectively; p < 0.001).  LNR also correlated with 5-year OS 
(69%, 48% and, 41% for Low-, Intermediate-, and High-risk groups respectively; p < 0.001). Significantly, LNR on 




Our findings support the use LNR as a predictor for OS for patients with EBC in Mid-Western Ireland.  LNR should be 
considered as an independent prognostic variable to the current prognostic instruments already in use.  In a SLNB and Z0011 
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